ReWalk Robotics (LFWD) 10-K 8 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 05, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	1,607,962
Amendment Flag	false
Trading Symbol	RWLK
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Public Float			$ 31,570,878
Entity Common Stock, Shares Outstanding		73,093,544

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 9,546	$ 14,567
Trade receivable, net	758	1,103
Prepaid expenses and other current assets	693	1,625
Inventories	2,240	3,643
Total current assets	13,237	20,938
LONG-TERM ASSETS
Restricted cash and other long term assets	1,099	1,085
Property and equipment, net	626	840
Total long-term assets	1,725	1,925
Total assets	14,962	22,863
CURRENT LIABILITIES:
Current maturities of long term loan	1,722	6,441
Trade payables	2,328	1,811
Employees and payroll accruals	650	872
Deferred revenues	237	123
Other current liabilities	445	480
Total current liabilities	5,382	9,727
LONG-TERM LIABILITIES
Long term loan, net of current maturities	6,965	8,911
Deferred revenues	431	262
Other long-term liabilities	239	256
Total long-term liabilities	7,635	9,429
Total liabilities	13,017	19,156
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity:
Ordinary share of NIS 0.01 par value-Authorized: 250,000,000 shares at December 31, 2018 and 2017; Issued and outstanding: 70,327,665 and 30,003,639 shares at December 31, 2018 and 2017, respectively	193	84
Additional paid-in capital	154,670	134,843
Accumulated deficit	(152,918)	(131,220)
Total shareholders' equity	1,945	3,707
Total liabilities and shareholders' equity	$ 14,962	$ 22,863

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Ordinary shares, par value (in NIS per share)	$ 0.01	$ 0.01
Ordinary shares, authorized	250,000,000	250,000,000
Ordinary shares, issued	70,327,665	30,003,639
Ordinary shares, outstanding	70,327,665	30,003,639

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Income Statement [Abstract]
Revenues	$ 6,545	$ 7,753	[1]	$ 5,869	[1]
Cost of revenues	3,720	4,652		5,133
Gross profit	2,825	3,101		736
Operating expenses:
Research and development, net	7,349	6,042		9,028
Sales and marketing	7,897	11,360		13,961
General and administrative	6,793	7,691		8,188
Total operating expenses	22,039	25,093		31,177
Operating loss	(19,214)	(21,992)		(30,441)
Loss on extinguishment of debt		313
Financial expenses, net	2,466	2,293		2,059
Loss before income taxes	(21,680)	(24,598)		(32,500)
Income taxes (tax benefit)	(5)	119		3
Net loss	$ (21,675)	$ (24,717)		$ (32,503)
Net loss per ordinary share, basic and diluted	$ (0.59)	$ (1.22)		$ (2.47)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted	36,812,476	20,214,895		13,178,107
[1]	As noted above, prior period amounts have not been adjusted under the modified retrospective method.

Statements of Changes In Shareh

Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands		Ordinary Share		Additional paid-in capital		Accumulated deficit	Total
Balance at Dec. 31, 2015		$ 33		$ 94,876		$ (73,989)	$ 20,920
Balance, shares at Dec. 31, 2015		12,222,583
Share-based compensation to employees and non-employees				3,398			3,398
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 1		17			18
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		128,496
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $468		$ 2		4,097			4,099
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $468, shares		692,062
Issuance of warrants to purchase ordinary shares				1,239			1,239
Cashless exercise of warrants into ordinary shares			[1]		[1]
Cashless exercise of warrants into ordinary shares, shares		45,116
Issuance of ordinary shares and warrants to purchase ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,099		$ 9		11,080			11,089
Issuance of ordinary shares and warrants to purchase ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,099, shares		3,250,000
Net loss						(32,503)	(32,503)
Balance at Dec. 31, 2016		$ 45		114,707		(106,492)	8,260
Balance, shares at Dec. 31, 2016		16,338,257
Share-based compensation to employees and non-employees				3,654			3,654
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 1		37			38
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		166,748
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $467		$ 16		9,293			9,309
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $467, shares		5,613,084
Issuance of ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,117		$ 22		7,141			7,163
Issuance of ordinary shares in follow-on public offering, net of issuance expenses in an amount of $1,117, shares		7,885,550
Cumulative effect to stock based compensation from adoption of a new accounting standard				11		(11)
Net loss						(24,717)	(24,717)
Balance at Dec. 31, 2017		$ 84		134,843		(131,220)	3,707
Balance, shares at Dec. 31, 2017		30,003,639
Share-based compensation to employees and non-employees				2,766			2,766
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees			[1]
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		429,515
Issuance of ordinary shares in investing agreement, net of issuance expenses in an amount of $830	[2]	$ 12		4,283			4,295
Issuance of ordinary shares in investing agreement, net of issuance expenses in an amount of $830, shares	[2]	4,117,891
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $236	[2]	$ 4		1,113			1,117
Issuance of ordinary shares in at-the-market offering, net of issuance expenses in the amount of $236, shares	[2]	1,247,172
Issuance of ordinary shares, warrants and pre-funded warrants in follow-on public offering, net of issuance expenses in an amount of $1,505	[2]	$ 49		11,528			11,577
Issuance of ordinary shares, warrants and pre-funded warrants in follow-on public offering, net of issuance expenses in an amount of $1,505, shares	[2]	18,200,498
Modification of warrants to purchase ordinary shares	[3]			18			18
Exercise of pre-funded warrants	[2]	$ 44		119			163
Exercise of pre-funded warrants, shares	[2]	16,328,950
Cumulative effect to accumulated deficit from adoption of a new accounting standard						(23)	(23)
Net loss						(21,675)	(21,675)
Balance at Dec. 31, 2018		$ 193		$ 154,670		$ (152,918)	$ 1,945
Balance, shares at Dec. 31, 2018		70,327,665
[1]	Represents an amount lower than $1.
[2]	See note 8b.
[3]	See note 8e.

Statements of Changes In Shar_2

Statements of Changes In Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Follow-on public offering
Issuance expenses, amount	$ 1,505	$ 1,117	$ 1,099
At-the-market offering
Issuance expenses, amount	236	$ 467	$ 468
Investing agreement
Issuance expenses, amount	$ 830

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows used in operating activities:
Net loss		$ (21,675)	$ (24,717)	$ (32,503)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		463	642	696
Share-based compensation to employees and non employees		2,766	3,654	3,398
Deferred taxes		(107)	73	(5)
Loss on extinguishment of debt			313
Loss on inducement of debt	[1]	600
Financial expenses related to long term loan		224	128	675
Capital Gain				(8)
Changes in assets and liabilities:
Trade receivables, net		322	151	892
Prepaid expenses and other current and long term assets		734	(438)	183
Inventories		1,403	(582)	(911)
Trade payables		492	(1,613)	950
Employees and payroll accruals		(222)	(147)	(202)
Deferred revenues		283	47	(32)
Other current and long term liabilities		(57)	27	120
Net cash used in operating activities		(14,774)	(22,462)	(26,747)
Cash flows used in investing activities:
Purchase of property and equipment		(13)	(21)	(452)
Proceeds from sale of property and equipment				15
Net cash used in investing activities		(13)	(21)	(437)
Cash flows from financing activities:
Issuance of ordinary shares upon exercise of options to purchase ordinary shares by employees and non-employees			38	18
Proceeds from long term loan				20,000
Debt issuance cost				(501)
Repayment of long term loan		(3,866)	(3,102)	(922)
Issuance of ordinary shares in investment agreement, net of issuance expenses in an amount of $830	[2]	4,295
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $211	[2]	1,142	9,309	4,099
Issuance of ordinary shares and exercise of pre-funded warrants into ordinary shares in follow-on offering, net of issuance expenses in an amount of $1,505 and net of long term loan conversion in the amount of $3,600	[1],[2]	8,140	7,163	11,089
Net cash provided by financing activities		9,711	13,408	33,783
Increase (decrease) in cash, cash equivalents, and restricted cash		(5,076)	(9,075)	6,599
Cash, cash equivalents, and restricted cash at beginning of period		15,423	24,498	17,899
Cash, cash equivalents, and restricted cash at end of period		10,347	15,423	24,498
Supplemental disclosures of non-cash flow information
Repayment of long term loan by issuance of units and pre-funded units	[1]	3,000
At-the-market offering expenses not yet paid	[2]	25
Classification of other current assets to property and equipment, net		236
Classification of inventory to property and equipment			203	181
Supplemental disclosures of cash flow information:
Cash and cash equivalents		9,546	14,567	23,678
Restricted cash included in other long term assets		801	856	820
Total Cash, cash equivalents, and restricted cash		10,347	15,423	24,498
Cash paid for income taxes		25	21	45
Cash paid for interest		$ 1,501	$ 2,300	$ 1,301
[1]	See note 6.
[2]	See note 8b.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Issuance expenses in an amount	$ 1,505
Long term loan conversion	3,600
Investment agreement
Issuance expenses paid	830
At-the-market offering
Issuance expenses paid	$ 211

General

General	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1:- GENERAL a. ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) (formerly Argo Medical Technologies GmbH) incorporated under the laws of Germany on January 14, 2013. c. The Company is designing, developing and commercializing the ReWalk system, an innovative exoskeleton that allow wheelchair-bound persons with mobility impairments or other medical conditions to stand and walk once again. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. There are currently two types of products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for the clinical rehabilitation environment where it provides valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal system in the future. d. The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States. RRG sell the Company’s products mainly in Germany and Europe. e. During the fiscal year ended December 31, 2018, the Company issued and sold 1,247,172 ordinary shares at an average price of $1.09 per share under its ATM Offering Program. The gross proceeds to the Company were $1.4 million, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $236 thousand were $1.1 million. The Company could raise up to $25 million under its ATM Offering Program. See Note 8b(1) below for more information about the Company’s ATM Offering Program. f. In November 2018, the Company completed its follow-on public offering in which the Company issued and sold 18,200,498 units, each consisting of one ordinary share and one warrant to purchase one ordinary share. Each unit was sold to the public at a price of $0.30 per unit. Additionally the company issued and sold 26,259,332 pre-funded units, each unit was sold to the public at a price of $0.29 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.01 per share and one warrant to purchase one ordinary share. The total gross proceeds received from the follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million. (including proceeds from the exercise of 2,267,284 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 14,061,666 ordinary shares had been exercised, for additional proceeds of $140,617. As compensation for their role in the offering, the Company also issued to the Underwriters warrants to purchase up to 2,667,590 ordinary shares, which are immediately exercisable starting on November 20, 2018 until November 15, 2023 at $0.375 per share. See Note 8c(2) below for more information about the Company’s follow-on public offering. g. In November 20, 2018, the Company and Kreos entered into the Second Amendment of the Loan Agreement. In the Second Amendment, the Company agreed to repay $3.6 million to Kreos in satisfaction of all outstanding indebtedness under the Kreos Convertible Note and other related payments, including prepayment costs and “end of loan” payments, and Kreos agreed to terminate the Kreos Convertible Note. The Company repaid Kreos the $3.6 million by issuing to Kreos 4,800,000 units and 7,200,000 pre-funded units at the applicable public offering prices for an aggregate price of $3.6 million (including the aggregate exercise price for the ordinary shares to be received upon exercise of the pre-funded warrants, assuming Kreos exercises all of the pre-funded warrants it purchased) as part of the Company’s public offering. Additionally, Kreos and the Company entered into the First Amendment to the Warrant to Purchase Shares, which amended the exercise price of the warrant to purchase 167,012 ordinary shares currently held by Kreos from $9.64 to $0.30. h. The Company depends on one contract manufacturer, Sanmina. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. i. The Company has an accumulated deficit in the total amount of $152.9 million as of December 31, 2018, negative cash flow from operations of $14.8 million, and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, issuances under the Company’s ATM Offering Program, or other future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company require more funds than anticipated during the next 12 months or in later periods. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The consolidated financial statements for the year ended December 31, 2018 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis, as follows: a. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards and warrants, contingent liabilities, provision for warranty, allowance for doubtful account and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. b. Financial Statements in U.S. Dollars: Most of the revenues and costs of the Company are denominated in United States dollars (“dollars”). Some of the Company’s and its subsidiaries’ revenues and costs are incurred in Euros and New Israeli Shekels (“NIS”), however, the selling prices are linked to the Company’s price list which is determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiaries’ functional and reporting currency. Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the consolidated statements of operations as appropriate. c. Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, RRI and RRG. All intercompany transactions and balances have been eliminated upon consolidation. d. Cash Equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired. e. Inventories: Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to historical, current and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its market value. Cost is determined as follows: Finished products - on the basis of raw materials and manufacturing costs on an average basis. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. In the years ended December 31, 2018, 2017 and 2016, the Company wrote off inventory in the amount of $562 thousand, $131 thousand and $237 thousand, respectively. If actual demand for the Company’s products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required. f. Related parties transactions and balances: The Company has a related party shareholder named Yaskawa Electric Corporation (“YEC”). In September 2013 the Company entered into a share purchase agreement and a strategic alliance with YEC, pursuant to which YEC has agreed to distribute the Company’s products, in addition to providing sales, marketing, service and training functions, in Japan, China (including Hong-Kong and Macau), Taiwan, South Korea, Singapore and Thailand. As of December 31, 2018 and 2017 the related party receivable were 0% of trade receivable, net, in both years. Revenues from YEC during the years ended December 31, 2018, 2017 and 2016 amounted to $13 thousand, $0 and $295 thousand, respectively. g. Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computer equipment 20-33 (mainly 33) Office furniture and equipment 6 - 10 (mainly 10) Machinery and laboratory equipment 15 Field service units 50 Leasehold improvements Over the shorter of the lease h. Impairment of Long-Lived Assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2018, 2017 and 2016, no impairment losses have been recorded. i. Restricted cash and Other long term assets: Other long term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions. j. Revenue Recognition: The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. On January 1, 2018, we adopted Topic 606 using the modified retrospective method for contracts that were not completed as of January 1, 2018. Under the modified retrospective method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This adjustment did not have a material impact on our consolidated financial statements. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Revenue Recognition (“Topic 605”). The adoption of Topic 606 represents a change in accounting principle that will provide financial statement readers with enhanced revenue recognition disclosures. In accordance with Topic 606, revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration to which we expect to be entitled in exchange for transferring products or providing services. To achieve this core principle, the Company applies the following five steps: 1. Identify the contract with a customer A contract with a customer exists when (i) the Company enters into a written agreement with a customer that defines each party’s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) both parties to the contract are committed to perform their respective obligations, (iii) the contract has commercial substance, and (iv) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s payment history or, in the case of a new customer, published credit and financial information pertaining to the customer. 2. Identify the performance obligations in the contract Performance obligations promised in a contract are identified based on the products or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the product or service either on its own or together with other resources that are readily available from the Company, and are distinct in the context of the contract, whereby the transfer of the products or services is separately identifiable from other promises in the contract. 3. Determine the transaction price The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. To the extent the transaction price is variable, revenue is recognized at an amount equal the consideration to which the Company expects to be entitled. This estimate includes customer sales incentives which are accounted for as a reduction to revenue and estimated using either the expected value method or the most likely amount method, depending on the nature of the program. As a result of the Company’s adoption of this standard, the majority of the amounts that were historically classified as bad debt expense, primarily related to self-payers customers, are now considered an implicit price concession in determining net revenue. Accordingly, the Company recognized uncollectible balances associated with self-payers customers as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within general and administrative expenses. Shipping and handling costs charged to customers are included in net sales. Determining the transaction price requires significant judgment, which is discussed by revenue category in further detail below. In practice, we do not offer extended payment terms beyond one year to customers. As such, we do not adjust our consideration for financing arrangements. 4. Allocate the transaction price to performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis unless a portion of the variable consideration related to the contract is allocated entirely to a performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. 5. Recognize revenue when or as the Company satisfies a performance obligation The Company generally satisfies performance obligations at a point in time, once the customer has obtained the legal title to the items purchased or service provided. For systems sold to rehabilitation facilities, the Company includes training and considers the elements in the arrangement to be a single performance obligation. In accordance with ASC 606, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed. For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery. Revenue is recognized based on the transaction price at the time the related performance obligation is satisfied by transferring a promised product or service to a customer. The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience. Disaggregation of Revenues Year Ended December 31, 2018 2017 (1) 2016 (1) Units placed 6,237 7,490 5,670 Spare parts and warranties 308 263 199 Total Revenues 6,545 7,753 5,869 (1) As noted above, prior period amounts have not been adjusted under the modified retrospective method. Units placed We currently offer two products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is currently designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides individuals access to valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal in the future. Units placed includes revenue from sales of a ReWalk Personal or ReWalk Rehabilitation. We also offer a Rent-to-Purchase model in which we recognize revenue ratably according to the agreed rental monthly fee. For units placed, we transfer control and recognize a sale when title has passed to our customer and rental revenue ratably according to the agreed rental monthly fee. Each unit placed is considered an independent, unbundled performance obligation. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. For spare part sales, we transfer control and recognize a sale when title has passed to our customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, we updated our service policy to include a five-year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. Contract balances December 31, December 31, 2018 2017 Trade receivable, net $ 758 $ 1,103 Short and Long term deferred revenues (1) $ 668 $ 384 (1) $135 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the year ended December 31, 2018. In addition to the above revenue recognition timing impacts, ASC 606 requires incremental contract acquisition costs (such as sales commissions) for customer contracts to be capitalized and amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the assets relates. Previously, these costs were expensed as incurred. Typical timing of payment The timing of satisfaction of our performance obligations does not significantly vary from the typical timing of payment. Typical payment terms are based on payment terms as established in our contracts. For some contracts we may be entitled to receive an advance payment. Transaction price allocated to remaining performance obligations for the year ended December 31, 2018, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. The Company’s unfilled performance obligations as of December 31, 2018 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $676 thousand, which is fulfilled over one to five years. k. Accounting for Share-Based Compensation: The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation-Stock Compensation” (“ASC No. 718”). ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. Effective as of January 1, 2017, the Company adopted Accounting Standards Update 2016-09, “Compensation-Stock Compensation (Topic 718)” (“ASU 2016-09”) on a modified, retrospective basis. ASU 2016-09 permits entities to make an accounting policy election related to how forfeitures will impact the recognition of compensation cost for stock-based compensation: to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures as they occur. Upon adoption of ASU 2016-09, the Company elected to change its accounting policy to account for forfeitures as they occur. The change was applied on a modified, retrospective basis with a cumulative-effect adjustment to retained earnings of $11 thousand (which increased the accumulated deficit) as of January 1, 2017. ASU 2016-09 also eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. The implementation resulted with no cumulative-effect adjustment to retained earnings as of January 1, 2017. Additionally, ASU 2016-09 addresses the presentation of excess tax benefits and employee taxes paid on the statement of cash flows. The Company is now required to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. The Company adopted this change prospectively. The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. Following the IPO in September 2014, the fair value of ordinary shares is observable as they are publicly traded. The fair value of Restricted Stock Units (RSUs) granted is determined based on the price of the Company’s ordinary shares on the date of grant. The fair value for options granted in 2018, 2017 and 2016 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions: December 31, 2018 2017 2016 Expected volatility 57% - 61 % 55% - 59 % 53% - 60 % Risk-free rate 2.74% - 2.83 % 1.78% - 2.07 % 1.16% - 1.60 % Dividend yield — % — % — % Expected term (in years) 6.11 5.31 - 6.11 5.31 - 6.11 Share price $ 1.02 - $1.15 $ 1.30 - $2.00 $ 6.80 - $11.88 The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model. The non-cash compensation expenses related to non-employees for the years ended December 31, 2018, 2017 amounted to $90 thousand and $45 thousand respectively, in 2016 the non-cash compensation expenses related to non-employees were immaterial. The non-cash compensation expenses related to employees and non- employees for the years ended December 31, 2018, 2017 and 2016 amounted to $2,766 thousand, $3,654 thousand and $3,398 thousand respectively. l. Research and Development Costs: Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the company receive for research and development in the period in which the grant was received. m. Income Taxes The Company accounts for income taxes in accordance with ASC No. 740, “Income Taxes” (“ASC No. 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. ASC No. 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. n. Warranty: The Company provides a two-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2017 $ 488 Provision 185 Usage (369 ) Balance at December 31, 2018 $ 304 o. Concentrations of Credit Risks: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables. The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. December 31, 2018 2017 Customer A * ) 14 % Customer B * ) 17 % Customer C * ) 10 % Customer D 28 % * ) Customer E 15 % * ) Customer F 14 % * ) Customer G 13 % * ) Customer H 12 % * ) *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of December 31, 2018 and 2017 trade receivables are presented net of $32 thousand and $125 thousand allowance for doubtful accounts, respectively, and net of sales return reserve of $105 thousand. p. Accrued Severance Pay: Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet. Total Company expenses related to severance pay amounted to $169 thousand, $185 thousand and $226 thousand for the years ended December 31, 2018, 2017 and 2016, respectively. q. Fair Value Measurements: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows: ● Level 1. ● Level 2. ● Level 3. The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments. r. Basic and Diluted Net Loss Per Share: Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of ordinary shares, including stock options, convertible preferred share warrants, to the extent dilutive, all in accordance with ASC No. 260, “Earning Per Share”. The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data): Year ended December 31, 2018 2017 2016 Net loss $ (21,675 ) $ (24,717 ) $ (32,503 ) Net loss attributable to ordinary shares (21,675 ) (24,717 ) (32,503 ) Shares used in computing net loss per ordinary shares, basic and diluted 36,812,476 20,214,895 13,178,107 Net loss per ordinary share, basic and diluted $ (0.59 ) $ (1.22 ) $ (2.47 ) Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares outstanding would have been anti-dilutive. s. Contingent liabilities The Company accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. See note 7e for further information. t. Government grants Government grants received by the Company relating to categories of operating expenditures are credited to the consolidated statements of operations during the period in which the expenditure to which they relate is charged. Royalty and non-royalty-bearing grants from the Israel Innovation Authority, or the IIA, (formerly known as the Israeli Office of the Chief Scientist), from the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”) and from the Israeli Fund for Promoting Overseas Marketing for funding certain approved research and development projects and sales and marketing activities are recognized at the time when the Company is entitled to such grants, on the basis of the related costs incurred, and are included as a deduction from research and development or sales and marketing expenses (see Note 7c). The Company received royalty-bearing grants in the amount of $198 and $1,030 for the years ended December 31, 2018, 2017. No royalty-bearings grants were recorded for the year ended December 31, 2016, respectively, as part of the research and development expenses. The Company recorded no royalty expenses for the years ended December 31, 2018, 2017 and 2016, respectively, as part of the cost of revenues. u. New Accounting Pronouncements Recently Implemented Accounting Pronouncements i. Revenues In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance, including industry-specific guidance. The core principle is that an entity will recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The standard provides a five-step model to be applied to all contracts with customers, which steps are to (1) identify the contract(s) with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when each performance obligation is satisfied. The Company adopted ASU 2014-09 as of the January 1, 2018 using the modified retrospective transition method with a cumulative-effect adjustment to equity. The adoption of this new standard may result in a change in the timing of revenue recognition related to certain of the company’s contracts. The most significant impact of the new standard relates to the way t

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2018
Prepaid Expense and Other Assets, Current [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 3:- PREPAID EXPENSES AND OTHER CURRENT ASSETS The components of prepaid expenses and other current assets are as follows (in thousands): December 31, 2018 2017 Government institutions $ 167 $ 191 Prepaid expenses 155 342 Advances to vendors 371 634 Other assets — 458 $ 693 $ 1,625

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4:- INVENTORIES The components of inventories are as follows (in thousands): December 31, 2018 2017 Finished products $ 2,240 $ 3,643 $ 2,240 $ 3,643

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 5:- PROPERTY AND EQUIPMENT, NET The components of property and equipment, net are as follows (in thousands): December 31, 2018 2017 Cost: Computer equipment $ 712 $ 709 Office furniture and equipment 293 293 Machinery and laboratory equipment 593 583 Field service units 1,246 1,010 Leasehold improvements 333 333 $ 3,177 $ 2,928 December 31, 2018 2017 Accumulated depreciation 2,551 2,088 Property and equipment, net $ 626 $ 840 Depreciation expenses amounted to $463 thousand, $642 thousand and $696 thousand for the years ended December 31, 2018, 2017 and 2016, respectively.

Loan Agreement with Kreos and R

Loan Agreement with Kreos and Related Warrant to Purchase Ordinary Shares	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES	NOTE 6:- LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES On December 30, 2015, the Company entered into the loan agreement (the “Loan Agreement”) with Kreos Capital V (Expert Fund) Limited (“Kreos”), pursuant to which Kreos extended a line of credit to the Company in the amount of $20 million. The Loan has a maturity of 36 months and bears annual interest of 10.75%, which is to be paid monthly. The principal of the Loan is to be paid in 24 monthly payments, beginning in January 2017, except for the last loan payment, which was paid in advance on the applicable draw down date. The repayment period will be extended to 36 months if the Company raises $20.0 million or more in connection with the issuance of shares of its capital stock (including debt securities convertible into shares of the Company’s capital stock) prior to the expiration of the respective initial 24-month period. Repayment of the Loan and payment of all other amounts owed to Kreos are to be made in U.S. dollars. On June 9, 2017, the Company and Kreos entered into the First Amendment of the Loan Agreement (the “Loan Amendment”). As of that date the outstanding principal amount under the Loan Agreement (the “Outstanding Principal Amount”) was $17.2 million. Under the Loan Amendment $3 million of the Outstanding Principal Amount was extended by an additional 3 years with the same interest rate and became subject to repayment in accordance with, and subject to the terms of, a secured convertible promissory note (the “Kreos Convertible Note”). The Kreos Convertible Note may be converted into up to 2,523,660 ordinary shares of the Company at a fixed conversion price of $1.268 per share (subject to customary antidilution adjustments in connection with a share split, reverse share split, share dividend, combination, reclassification or otherwise), thus reducing the Outstanding Principal Amount by $3 million to $14.2 million. Kreos may convert the then-outstanding principal under the Kreos Convertible Note in whole or in part, in one or more occasions, at any time until the earlier of (i) the maturity date of June 9, 2020 or (ii) a “Change of Control”, as defined in the Loan Agreement. In addition, at any time until the maturity date of June 9, 2020, Kreos has the right to convert the “end of loan payments” under the Loan Agreement, in whole or in part, into ordinary shares at a conversion price of $1.268 per share. Because the aggregate amount the Company drew down under the Loan Agreement equals $20 million and the total “end of loan payments” equal $200 thousand, Kreos has the right to convert up to 157,729 additional ordinary shares (subject to customary anti-dilution adjustments), making the total number of ordinary shares issuable upon conversion of the Kreos Convertible Note 2,523,660 (subject to customary anti-dilution adjustments). The Outstanding Principal Amount under the Loan Agreement is not convertible and remains subject to repayment in accordance with the terms and conditions of the Loan Agreement, provided that such amount shall be repaid by the Company in accordance with an amended repayment schedule. The Company concluded that the exchange of the $3 million for the convertible promissory note is not a troubled debt restructuring under applicable accounting guidance because the lenders did not grant a concession. The modification was analyzed under ASC 470 Debt According to the Loan Agreement the repayment period will be extended to 36 months if the Company raises $20 million or more in connection with the issuance of shares of its capital stock (including debt securities convertible into shares of the Company’s capital stock). As of June 30, 2017 the Company had raised more than $20 million and therefore the repayment period was extended by an additional 12 months to 36 months. On November 20, 2018, the Company and Kreos entered into the Second Amendment of the Loan Agreement (the “Second Amendment”). In the Second Amendment, the Company agreed to repay $3.6 million to Kreos in satisfaction of all outstanding indebtedness under the Kreos Convertible Note and other related payments, including prepayment costs and “end of loan payments”, and Kreos agreed to terminate the Kreos Convertible Note. The Company paid Kreos the $3.6 million by issuing to Kreos 4,800,000 units and 7,200,000 pre-funded units at the applicable public offering prices for an aggregate price of $3.6 million (including the aggregate exercise price for the ordinary shares to be received upon exercise of the pre-funded warrants, assuming Kreos exercises all of the pre-funded warrants it purchased) as part of the Company’s public offering. The Company and Kreos also agreed to revise the principal and the repayment schedule under the Kreos Loan Agreement. Additionally, Kreos and the Company entered into the First Amendment to the Warrant to Purchase Shares (the “Kreos Warrant Amendment”), which amended the exercise price of the warrant to purchase 167,012 ordinary shares currently held by Kreos from $9.64 to $0.30. The revised repayment schedule, effectively deferred an additional $1.1 million of payments that were due in 2018 and $2.8 million that were due in 2019 under the loan’s prior repayment schedule, for total deferred payments of $3.9 million compared to the prior repayment schedule. The loan repayment schedule was extended for a period of three months. As of December 31, 2018, the outstanding principal amount under the Kreos Loan Agreement was $8.7 million. The Second Amendment also made certain changes to the prepayment premiums under the Kreos Loan Agreement, tying them to the date of the Second Amendment. Under ASC 470-50 a modification treatment is applicable. The warrants amended exercise price was treated under ASC 470-50-10 as modification and therefore were capitalized and will be amortized as part of the effective yield. Under ASC 470-20-40-14, the loan repayment of the $3.0 million for the convertible promissory note (converted into units and pre-funded units as stated above) was treated as inducement of debt, upon which the Company recorded $672 thousands as finance expenses in the consolidated statements of operations during the fiscal year ended December 31, 2018, of which $72 thousands due upon exercise of the pre-funded warrants are presented as part of the Company’s other current liabilities. The Company recorded interest expense in the amount of $2.4 million during the fiscal year ended December 31, 2018.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 7:- COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitment: The Company has contractual obligations to purchase goods from its contract manufacturer. Purchase obligations do not include contracts that may be canceled without penalty. As of December 31, 2018, non-cancelable outstanding obligations amounted to approximately $350 thousand. b. Lease commitment: the Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2019 and 2023. The future minimum lease commitments from leased facilities and cars of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises, that are in effect as of December 31, 2018, are as follows: 2019 545 2020 544 2021 553 2022 562 2023 438 And Thereafter — Total $ 2,642 Total rent expenses for the years ended December 31, 2018, 2017 and 2016 were $695 thousand, $682 thousand and $650 thousand, respectively. RRL lease cars for its employees under cancelable operating lease agreements expiring at various dates in 2019-2021. RRL has an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $39 thousand as of December 31, 2018. c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the IIA and BIRD. Since the Company’s inception through December 31, 2018, the Company received funding from the IIA and BIRD in the total amount of $1.97 million and $500 thousand, respectively. Out of the $1.97 million in funding from the IIA, a total amount of $1.57 million were royalty bearing grants (as of December 31, 2018, the Company paid royalties to the IIA in the total amount of $50 thousand), while a total amount of $400 thousand was received in consideration of 5,237 convertible preferred A shares, which converted after our initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1. The Company is obligated to pay royalties to the IIA, amounting to 3%-3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. The Company was obligated to pay royalties to the BIRD amounting to 5% of the sales of the products and other related revenues generated from such projects, up to 150% of the grants received. For the years ended December 31, 2018, 2017 and 2016 no royalties expenses recorded in cost of revenues. As of December 31, 2018, the contingent liability to the IIA amounted to $1.5 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including certain intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests. The Company’s other long-term assets in the amount of $801 thousand have been pledged as security in respect of a guarantee granted to a third party . e. Legal Claims: Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of the company’s defenses and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition. As previously disclosed, between September 2016 and January 2017, eight putative class actions on behalf of alleged shareholders that purchased or acquired our ordinary shares pursuant and/or traceable to our registration statement on Form F-1 (File No. 333-197344) used in connection with our initial public offering, or our IPO, were commenced in the following courts: (i) the Superior Court of the State of California, County of San Mateo; (ii) the Superior Court of the Commonwealth of Massachusetts, Suffolk County; (iii) the United States District Court for the Northern District of California; and (iv) the United States District Court for the District of Massachusetts. As of November 14, 2018, seven have been dismissed and one has been partially dismissed. The actions involved or involve claims under various sections of the Securities Act against us, certain of our current and former directors and officers, the underwriters of our IPO and certain other defendants. The four actions commenced in the Superior Court of the State of California, County of San Mateo were dismissed in January 2017 for lack of personal jurisdiction, and the action commenced in the United States District Court for the Northern District of California was voluntarily dismissed in March 2017. Additionally, the two actions commenced in the Superior Court of the Commonwealth of Massachusetts, Suffolk County, or the Superior Court, were consolidated in December 2017, and voluntarily dismissed with prejudice in November 2018, after the District Court for the District of Massachusetts partially dismissed the related claims in that court and the parties in the Superior Court entered a stipulation of dismissal with prejudice. The action commenced in the United States District Court for the District of Massachusetts (the “District Court”), alleging violations of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, was partially dismissed on August 23, 2018. In particular, the District Court granted the motion to dismiss the claims under Sections 11 and 15 of the Securities Act, finding that the plaintiff failed to plead a false or misleading statement in the IPO registration statement. The District Court did not address the claims under Sections 10(b) and 20(a) of the Exchange Act because, as a result of the dismissal of the claims under the Securities Act, the lead plaintiff lacked standing to pursue those claims. Because the action in the District Court was styled as a class action, the District Court permitted the plaintiff to file a supplemental memorandum concerning standing or a motion to appoint a substitute or supplemental plaintiff. On September 10, 2018, the plaintiff sought leave to amend his complaint to add a new plaintiff that purportedly has standing to pursue Exchange Act claims, and we opposed the motion to amend on September 24, 2018. Based on information currently available and the current stage of the litigation, we are unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to the remaining lawsuit in the District Court; therefore, no litigation reserve has been recorded in our consolidated balance sheets as of December 31, 2018. We will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times if and when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 8:- SHAREHOLDERS’ EQUITY a. Ordinary shares: The ordinary shares of the Company confer on the holders thereof voting rights, rights to receive dividends and rights to participate in distribution of assets upon liquidation after any outstanding preferred shares receive their preference amount. b. Equity raise: 1. At-the-market offering program: On May 10, 2016, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Jaffray, pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company’s Form S-3, in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “ATM Offering Program”). Sales may be made directly on or through the NASDAQ Capital Market, the existing trading market for the Company’s ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time. The Company may raise up to $25 million under its ATM Offering Program pursuant to the terms of its agreement with the sales agent. However, due to limitations under the rules of Form S-3, which have applied to the Company since it filed its annual report on Form 10-K, in February 2017, as of the date of this annual report we may only issue up to approximately $13.7 million in primary offerings under our effective registration statement on Form S-3 (the “Form S-3”), including our ATM Offering Program, during any 12-month period while we remain subject to these limitations. Because we have already sold $15.7 million in the ATM Offering Program since its inception, we may only raise up to a remaining $9.3 million using the program, subject to the $13.7 million cap during any rolling 12-month period. During the 12 months after the Company became subject to these rules, the Company issued and sold 1,247,172 ordinary shares at an average price of $1.09 per share under its ATM Offering Program. The gross proceeds to the Company were $1.4 million, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $236 thousand were $1.1 million. As a result, from the inception of the ATM Offering Program in May 2016 until December 31, 2018, the Company had sold 7,552,318 ordinary shares under the ATM Offering Program for gross proceeds of $15.7 million and net proceeds to the Company of $14.5 million (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation for the fixed commission rate of 3.0% in the aggregated amount of $471 thousand and had incurred total expenses of approximately $1,171 thousand in connection with the ATM Offering Program. 2. Follow-on offering In November 2017, the Company entered into the Underwriting Agreement with National Securities Corporation (“National”), in connection with the Company’s follow-on public offering of 6,857,000 ordinary shares. Each ordinary share was sold to the public at a price of $1.05 per share. On November 22, 2017 National exercised in full its option to purchase 1,028,550 additional ordinary shares at the public offering price of $1.05 per share, less the underwriting discount. The Company’s gross proceeds were $8.3 million. The Company’s net aggregate proceeds, after deducting underwriting discounts, commissions and expenses, were $7.2 million . In November 2018, the Company entered into the Underwriting Agreement with H.C. Wainwright & Co., LLC (“H.C. wainwright”), in connection with the Company’s follow-on public offering of 12,401,390 units, each consisting of one ordinary share and one warrant to purchase one ordinary share with an exercise price of $0.30 per warrant. Each unit was sold to the public at a price of $0.30 per unit. On November 18, 2018, H.C. wainwright exercised in full its option to purchase 5,799,108 ordinary shares for $0.29 per share and/or common warrants to purchase up to an additional 5,799,108 ordinary shares for $0.01 per warrant, in each case, less underwriting discounts and commission. Additionally the company issued and sold 26,259,332 pre-funded units, each unit was sold to the public at a price of $0.29 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.01 per share and one warrant to purchase one ordinary share with an exercise price of $0.30 per warrant. The total gross proceeds received from the follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million (including proceeds from the exercise of 2,267,284 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 14,061,666 ordinary shares had been exercised, for additional proceeds of $140,617. As compensation for their role in the offering, the Company also issued to the Underwriters warrants to purchase up to 2,667,590 ordinary shares, which are immediately exercisable starting on November 20, 2018 until November 15, 2023 at $0.375 per share. 3. Investment agreement On March 6, 2018, the Company entered into an investment agreement with Timwell Corporation Limited, a Hong Kong corporation (“Timwell”), as amended on May 15, 2018 (the “Investment Agreement”), pursuant to which the Company agreed to issue to Timwell, in three different tranches, an aggregate of 16,000,000 ordinary shares in return for aggregate gross proceeds of $20 million. The closing of each tranche is subject to certain closing conditions. The closing of the first tranche (the “First Tranche Closing”) took place on May 15, 2018, upon which Timwell received 4,000,000 ordinary shares for an aggregate purchase price of $5,000,000, and Timwell and the Company signed a registration rights agreement in the form attached to the Investment Agreement. The net aggregate proceeds of the First Tranche Closing after deducting fees and other related expenses in the amount of approximately $705 thousands were approximately $4.3 million. The remaining investment is to occur in two tranches, including $10 million for the issuance to Timwell of 8,000,000 ordinary shares (the “Second Tranche”) and $5 million for the issuance to Timwell of 4,000,000 ordinary shares (the “Third Tranch”). The closing of the second and third tranches is subject to specified closing conditions, including, with respect to the second tranche, the signing of a license agreement and a supply agreement and the formation of the China JV (the “China JV”) based on the JV Framework Agreement, and, with respect to the third tranche, the successful production of certain ReWalk products by the China JV. The second tranche closing was initially expected to occur by July 1, 2018 and the third tranche closing was initially expected to occur by December 31, 2018 and no later than April 1, 2019. In light of the positions taken by Timwell during the negotiations on definitive joint venture and license agreements, we no longer believe that agreement can be reached on the basis of the original understandings reflected in our Investment Agreement with Timwell. We remain in dialogue with RealCan, Timwell’s affiliate, and we are discussing with RealCan various alternative pathways to commercialize our products in China. Due to the various delays in the process and other barriers to closing we currently see a significant risk that we will not reach agreement with RealCan on a modification of the original agreement. As we continue to view China as a market with key opportunities for products designed for stroke patients, we are also evaluating potential relationships with other groups to penetrate the Chinese market. In May 2018, the Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the closing of the First Tranche of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the closing of the first tranche of the Timwell transaction in May 15, 2018, the Company issued 117,891 ordinary shares to Canaccord Genuity. In connection with the First Tranche Closing, on May 15, 2018, the Company also amended its exclusive distribution agreement with Yaskawa Electric Corporation (“Yaskawa”), dated September 24, 2013, to terminate the distribution rights granted to Yaskawa in China (including Hong Kong and Macau), as required by the Investment Agreement. c. Share Option Plans: On March 30, 2012, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2012 Equity Incentive Plan. On August 19, 2014, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan or the “Plan”. The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, cash-based awards, other stock-based awards and dividend equivalents to the Company’s and its affiliates’ respective employees, non-employee directors and consultants. Starting in 2014, the Company grants to directors and employees Restricted Stock Units (“RSUs”) under this Plan. An RSU award is an agreement to issue shares of the company’s ordinary shares at the time the award is vested. As of December 31, 2018 and 2017, the Company had reserved 1,535,634 and 1,301,521 shares of ordinary shares, respectively, available for issuance to employees, directors, officers and non-employees of the Company. The share reserve pool will increase on January 1 of each calendar year during the term of the 2014 Plan in an amount equal to the lesser of: (x) 972,000, (y) 4% of the total number of shares outstanding on December 31 of the immediately preceding calendar year, and (z) an amount determined by the Company’s board of directors. The options generally vest over four year, with certain options granted to non-employee directors during the fiscal year ended December 31, 2018, vesting over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the Plan. A summary of employee share options activity during the fiscal year ended 2018 is as follows: Number Average exercise price Average remaining contractual life (years) Aggregate intrinsic value (in thousands) Options outstanding at the beginning of the year 1,277,726 $ 2.69 6.33 $ 8 Granted 662,427 1.09 Exercised — — Forfeited (122,894 ) 5.54 Options outstanding at the end of the year 1,817,259 $ 1.91 6.37 $ — Options exercisable at the end of the year 1,033,602 $ 2.39 4.25 $ — A summary of employee RSUs activity during the fiscal year ended 2018 is as follows: Number of shares underlying outstanding RSUs Weighted- average grant date fair value Unvested RSUs at the beginning of the year 569,071 3.13 Granted 510,803 1.09 Vested (1) (342,820 ) 2.74 Forfeited (84,304 ) 2.59 Unvested RSUs at the end of the year 652,750 1.80 (1) During the fiscal year ended December 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested on a net basis was 340,367 ordinary shares. The weighted average grant date fair values of options granted during the fiscal year ended December 31, 2018, 2017 and 2016 were $0.61, $1.02 and $4.75 respectively. The weighted average grant date fair values of RSUs granted during the fiscal year ended December 31, 2018, 2017 and 2016, were $1.07, $1.44 and $9.28, respectively. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders, which hold options with positive intrinsic value, exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for the year ended December 31, 2017 and 2016 were $29 thousand and $844 thousand, respectively. During the year ended December 31, 2018 no options were exercised. Total fair value of shares vested during the year ended December 31, 2018, 2017 and 2016 were $2,918 thousand, $3,785 thousand and $3,626 thousand respectively. As of December 31, 2018, there were $1.9 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2012 and 2014 Plans. This cost is expected to be recognized over a period of approximately 2.0 years. The number of options and RSUs outstanding as of December 31, 2018 is set forth below, with options separated by range of exercise price: Range of exercise price Options and RSUs Outstanding as of December 31, 2018 Weighted average remaining contractual life (years) (1) Options Exercisable as of December 31, 2018 Weighted average remaining contractual life (years) (1) RSUs only 652,750 — — — $0.82 19,764 2.03 19,764 2.03 $1.32 980,355 7.38 322,928 3.42 $1.47-$2.10 718,800 5.04 597,093 4.35 $6.80-$8.99 66,941 7.05 63,000 7.06 $9.22-$10.98 14,046 7.32 13,577 7.33 $19.62-$20.97 17,353 5.97 17,240 5.97 2,470,009 6.37 1,033,602 4.25 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. On September 6, 2017, the Company commenced a one-time equity award exchange program (the “Equity Exchange Program”), offering to certain eligible employees, executive officers and consultants the opportunity to cancel certain outstanding “underwater” stock options issued under the 2014 Plan, in exchange for the grant under such plan of a lesser number of RSUs. The Company’s non-employee directors and retirees were not eligible to participate in the Equity Exchange Program. The Company conducted the Equity Exchange Program as a “value-for-value” exchange, pursuant to which the Company issued new RSUs with a value approximately equal to the value of the options that are surrendered, in accordance with the terms approved by the Company’s shareholders at the annual meeting of shareholders held on June 27, 2017. The primary purpose of the Equity Exchange Program was to restore the intended retention and incentive value of certain employee and consultant equity awards. Participation in the Equity Exchange Program was voluntary. The Company used the 52-week high closing price of its ordinary shares (as measured at the commencement of the Equity Exchange Program) as a threshold for options eligible to be exchanged. On the Equity Exchange Program’s expiration date of October 4, 2017, 46 holders tendered options to purchase an aggregate of 945,416 ordinary shares, representing 96.4% of all options eligible for exchange, and on October 5, 2017, the Company granted to these holders an aggregate of 251,872 new RSUs. 180,167 of these new RSUs were granted to the Company’s executive officers and “named executive officers” (as defined in Item 402 of Regulation S-K of the SEC). Unless the Company’s compensation committee accelerates their vesting, the new RSUs vest over a three-year period, with one-third vesting on the first anniversary of the date of grant and one-third vesting on each of the next two successive anniversaries. Additionally, the forfeiture terms of the new RSUs are substantially the same as those that apply generally to previously-granted RSUs granted under the 2014 Plan. The modification was analyzed under ASC No. 718 to determine if the new vesting condition remain probable, as the original. Since the modification also increased the fair value of the Equity Exchange Program, the Company decided to implement one of the two acceptable methods and recognize the incremental compensation amounted to $159 thousand over the new service period, while the unrecognized compensation cost remaining from the original grant will be recognized over the remainder of the original requisite service period. The stock options exchanged pursuant to the Exchange Program were canceled and the ordinary shares underlying such options became available for issuance under the 2014 Plan. d. Equity compensation issued to consultants: The Company granted 3,454 options to a non-employee consultant on March 12, 2007, which were exercised during the fiscal year ended December 31, 2018. The Company granted 89,148 fully vested RSUs during the fiscal year ended December 31, 2018 to non-employee consultants. As of December 31, 2018, there are no outstanding options or RSUs held by non-employee consultants. e. Warrants to purchase ordinary shares During the fiscal year ended December 31, 2018, 16,328,950 warrants were exercised into ordinary shares. The following table summarizes information about warrants outstanding and exercisable as of December 31, 2018: Issuance date Warrants outstanding Exercise price per warrant Warrants exercisable Exercisable through (number) (number) December 30, 2015 (1) (4) 119,295 $ 0.30 119,295 See footnote (1) November 1, 2016 (2) 2,437,500 $ 4.75 2,437,500 November 1, 2021 December 28, 2016 (3) (4) 47,717 $ 0.3 47,717 See footnote (1) November 20, 2018 (5) 44,459,830 $ 0.3 44,459,830 November 20, 2023. November 20, 2018 (6) 2,667,590 $ 0.375 2,667,590 November 15, 2023 November 20, 2018 (7) 9,930,382 $ 0.01 9,930,382 November 20, 2023. 59,662,314 59,662,314 (1) Represents warrants for ordinary shares issuable upon an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2018. (2) Represents warrants issued as part of our follow-on offering in November 2016. The exercise price and the number of ordinary shares into which the warrants may be exercised are subject to adjustment upon certain corporate events, including stock splits, reverse stock splits, combinations, stock dividends, recapitalizations, reorganizations and certain other events. Our board of directors may also determine to make such adjustments to the exercise price and number of ordinary shares to be issued upon exercise based on similar events, including the granting of stock appreciation rights, phantom stock rights or other rights with equity features. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (3) Represents warrants in the amount of 47,717 ordinary shares that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (4) On November 20, 2018, Kreos and the Company entered into the First Amendment to the Warrant to Purchase Shares (the “Kreos Warrant Amendment”), which amended the exercise price of the warrant to purchase 167,012 ordinary shares currently held by Kreos from $9.64 to $0.30. See note 6. (5) Represents warrants in the amount of 44,459,830 ordinary shares that were issued as part of our follow-on offering in November 2018. (6) Represents warrants to purchase up to 2,667,590 ordinary shares that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018. (7) Represents 26,259,332 pre-funded warrants with an exercise price of $0.01 per share. As of December 31, 2018, pre-funded warrants to purchase an aggregate 16,328,950 ordinary shares had been exercised. f. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense in the consolidated statements of operations as follows: Year Ended December 31, 2018 2017 2016 Cost of revenues $ 16 $ 62 $ 108 Research and development, net 435 508 559 Sales and marketing, net 467 963 811 General and administrative 1,848 2,121 1,920 Total $ 2,766 $ 3,654 $ 3,398

Research Collaboration Agreemen

Research Collaboration Agreement and License Agreement	12 Months Ended
	Dec. 31, 2018
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	NOTE 9:- RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement (“Collaboration Agreement”) and an Exclusive License Agreement (“License Agreement”) with Harvard. The Research Collaboration Agreement was amended on May 1, 2017 and April 1, 2018 (as amended, the “Collaboration Agreement”), and the Exclusive License Agreement was amended on April 1, 2018 (as amended, the “License Agreement”), to extend the term of the Collaboration Agreement by one year to May 16, 2022 and reallocate the Company’s quarterly installment payments to Harvard through such date, and to make certain technical changes. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2021. Under the Harvard License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The Harvard License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of December 31, 2018, in light of the achievement of a milestone, the Company recorded a liability which is included in the total expenses recorded during the three and twelve months ended December 31, 2018. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis. Moreover, since such royalties are dependent on future product sales which are neither determinable nor reasonably estimable, these royalty payments are not recorded on the Company’s consolidated balance sheet as of December 31, 2018. The Company’s total payment obligation under the Collaboration Agreement and the Harvard License Agreement is $6.5 million, some of which is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expenses in the amount of $0.9 million which is part of the total payment obligation indicated above, as research and development expenses related to the Harvard License Agreement and to the Collaboration Agreement for the fiscal year ended December 31, 2018. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10:- INCOME TAXES The Company’s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity. a. Corporate tax rates in Israel: Presented hereunder are the tax rates relevant to the Company in the years 2016-2018: The Israeli statutory corporate tax rate and real capital gains were 23% in 2018, 24% in 2017 and 25.0% in 2016 In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% effective from January 1, 2017 and to 23% effective from January 1, 2018. b. Loss before taxes on income is comprised as follows: Year Ended December 31, 2018 2017 2016 Domestic $ (21,784 ) $ (24,728 ) $ (32,642 ) Foreign 104 130 142 $ (21,680 ) $ (24,598 ) $ (32,500 ) c. Taxes on income are comprised as follows: Year Ended December 31, 2018 2017 2016 Current $ 102 $ 46 $ 8 Deferred (107 ) 73 (5 ) $ (5 ) $ 119 $ 3 Year Ended December 31, 2018 2017 2016 Domestic $ — $ — $ — Foreign (5 ) 119 3 $ (5 ) $ 119 $ 3 d. Deferred income taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets as of December 31, 2018 and 2017 are derived from temporary differences. In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company’s history of losses, the Company established a full valuation allowance for RRL. Undistributed earnings of certain subsidiaries as of December 31, 2018 were immaterial. The Company intends to reinvest these earnings indefinitely in the foreign subsidiaries. As a result, the Company has not provided for any deferred income taxes. December 31, 2018 2017 Carry forward tax losses $ 28,033 $ 24,969 Research and development carry forward expenses-temporary differences 1,567 1,282 Accrual and reserves 241 139 Deferred tax assets before valuation allowance 29,841 26,390 Valuation allowance (29,655 ) (26,311 ) Net deferred tax assets $ 186 $ 79 The net changes in the total valuation allowance for each of the years ended December 31, 2018, 2017 and 2016, are comprised as follows: Year Ended December 31, 2018 2017 2016 Balance at beginning of year $ (26,311 ) $ (22,560 ) $ (16,196 ) Changes due to amendments to tax laws and exchange rate differences 1,393 1,806 917,000 Adjustment previous year loss — (591 ) — Additions during the year (4,737 ) (4,966 ) (7,281 ) Balance at end of year $ (29,655 ) $ (26,311 ) $ (22,560 ) e. Reconciliation of the theoretical tax expenses: A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows: Year Ended December 31, 2018 2017 2016 Loss before taxes, as reported in the consolidated statements of operations $ (21,680 ) $ (24,598 ) $ (32,500 ) Statutory tax rate 23.0 % 24.0 % 25.0 % Theoretical tax benefits on the above amount at the Israeli statutory tax rate $ (4,986 ) $ (5,904 ) $ (8,125 ) Income tax at rate other than the Israeli statutory tax rate 5 17 10 Non-deductible expenses including equity based compensation expenses and other 631 878 857 Operating losses and other temporary differences for which valuation allowance was provided 4,737 4,966 7,281 Other (392 ) 162 (20 ) Actual tax expense $ (5 ) $ 119 $ 3 f. Foreign tax rates: Taxable income of RRI was subject to tax at the rate of 21% in 2018 and 2017 and at the rate of 40% in 2016. The effect of the tax rate change on the Company’s deferred tax expense in 2017 was $58 thousand. Taxable income of RRG was subject to tax at the rate of 30% in 2018, 2017, and 2016. g. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”): Conditions for entitlement to the benefits: Under the Investment Law, in 2012 the Company elected “Beneficiary Enterprise” status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate. Income derived from Beneficiary Enterprise from productive activity will be exempt from tax for ten years from the year in which the Company first has taxable income, providing that 12 years have not passed from the beginning of the year of election. In the event of a dividend distribution from income that is exempt from company tax, as aforementioned, the Company will be required to pay tax of 10%- 25% on that income. In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the rate ordinarily applicable to the Beneficiary Enterprise’s income. Tax-exempt income generated under the Company’s “Beneficiary Enterprise” program will be subject to taxes upon dividend distribution or complete liquidation. The entitlement to the above benefits is conditional upon the Company’s fulfilling the conditions stipulated by the Law and regulations published thereunder. On December 29, 2010, the Knesset approved an additional amendment to the Law for the Encouragement of Capital Investments, 1959. According to the amendment, a reduced uniform corporate tax rate for exporting industrial enterprises (over 25%) was established. The reduced tax rate will not be program dependent and will apply to the industrial enterprise’s entire income. The tax rates for industrial enterprises have been reduced. In August 2013, the Israeli Knesset approved an amendment to the Investment Law, pursuant to which the rates for development area A will be 9% and for the rest of the country- 16% in 2014 and thereafter. The Amendment also prescribes that any dividends distributed to individuals or foreign residents from a preferred enterprise’s earnings as above will be subject to taxes at a rate of 20% (subject to tax treaty benefits) In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law for the Encouragement of Capital Investments (“the Amendment”) was published. According to the Amendment, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2017 (and thereafter the tax rate applicable to preferred enterprises located in other areas remains at 16%). The Company has examined the effect of the adoption of the Amendment on its financial statements, and as of the date of the publication of the financial statements, the Company estimates that it will not apply the Amendment. The Company’s estimate may change in the future. h. Tax assessments: RRL has had final tax assessments up to and including the 2012 tax year. Each RRI and RRG have not had final tax assessment, since its inception. i. Net operating carry-forward losses for tax purposes: As of December 31, 2018, RRL has carry-forward losses amounting to approximately $121.9 million, which can be carried forward for an indefinite period, and RRI has carry-forward losses amounting to approximately $140 thousands, which can be carried forward for a period of 20 years.

Financial Expenses, Net

Financial Expenses, Net	12 Months Ended
	Dec. 31, 2018
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES, NET	NOTE 11:- FINANCIAL EXPENSES, NET The components of financial expenses, net were as follows: Year Ended December 31, 2018 2017 2016 Foreign currency transactions and other $ 42 $ (188 ) $ 85 Financial expenses related to loan agreement with Kreos 2,398 2,451 1,976 Bank commissions 26 30 34 Income related to hedging transactions — — (36 ) $ 2,466 $ 2,293 $ 2,059

Geographic Information and Majo

Geographic Information and Major Customer and Product Data	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	NOTE 12:- GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas: Year Ended December 31, 2018 2017 2016 Revenues based on customer’s location: Israel $ — $ — $ — United States 3,558 4,598 3,741 Europe 2,807 3,094 1,144 Asia-Pacific 22 61 984 Latin America 58 — — Africa 100 — — Total revenues $ 6,545 $ 7,753 $ 5,869 December 31, 2018 2017 Long-lived assets by geographic region: Israel $ 206 $ 298 United States 330 342 Germany 90 200 $ 626 $ 840 (*) Long-lived assets are comprised of property and equipment, net. Major customer data as a percentage of total revenues: Year Ended December 31, 2018 2017 2016 Customer A 38.0 % 35.2 % 33.3 %

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	a. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards and warrants, contingent liabilities, provision for warranty, allowance for doubtful account and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
Financial Statements in U.S. Dollars	b. Financial Statements in U.S. Dollars: Most of the revenues and costs of the Company are denominated in United States dollars (“dollars”). Some of the Company’s and its subsidiaries’ revenues and costs are incurred in Euros and New Israeli Shekels (“NIS”), however, the selling prices are linked to the Company’s price list which is determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiaries’ functional and reporting currency. Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the consolidated statements of operations as appropriate.
Principles of Consolidation	c. Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, RRI and RRG. All intercompany transactions and balances have been eliminated upon consolidation.
Cash Equivalents	d. Cash Equivalents: Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.
Inventories	e. Inventories: Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to historical, current and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its market value. Cost is determined as follows: Finished products - on the basis of raw materials and manufacturing costs on an average basis. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. In the years ended December 31, 2018, 2017 and 2016, the Company wrote off inventory in the amount of $562 thousand, $131 thousand and $237 thousand, respectively. If actual demand for the Company’s products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required.
Related parties transactions and balances	f. Related parties transactions and balances: The Company has a related party shareholder named Yaskawa Electric Corporation (“YEC”). In September 2013 the Company entered into a share purchase agreement and a strategic alliance with YEC, pursuant to which YEC has agreed to distribute the Company’s products, in addition to providing sales, marketing, service and training functions, in Japan, China (including Hong-Kong and Macau), Taiwan, South Korea, Singapore and Thailand. As of December 31, 2018 and 2017 the related party receivable were 0% of trade receivable, net, in both years. Revenues from YEC during the years ended December 31, 2018, 2017 and 2016 amounted to $13 thousand, $0 and $295 thousand, respectively.
Property and Equipment	g. Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: % Computer equipment 20-33 (mainly 33) Office furniture and equipment 6 - 10 (mainly 10) Machinery and laboratory equipment 15 Field service units 50 Leasehold improvements Over the shorter of the lease
Impairment of Long-Lived Assets	h. Impairment of Long-Lived Assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2018, 2017 and 2016, no impairment losses have been recorded.
Restricted cash and Other long term assets	i. Restricted cash and Other long term assets: Other long term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.
Revenue Recognition	j. Revenue Recognition: The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. On January 1, 2018, we adopted Topic 606 using the modified retrospective method for contracts that were not completed as of January 1, 2018. Under the modified retrospective method, we recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. This adjustment did not have a material impact on our consolidated financial statements. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Revenue Recognition (“Topic 605”). The adoption of Topic 606 represents a change in accounting principle that will provide financial statement readers with enhanced revenue recognition disclosures. In accordance with Topic 606, revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration to which we expect to be entitled in exchange for transferring products or providing services. To achieve this core principle, the Company applies the following five steps: 1. Identify the contract with a customer A contract with a customer exists when (i) the Company enters into a written agreement with a customer that defines each party’s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) both parties to the contract are committed to perform their respective obligations, (iii) the contract has commercial substance, and (iv) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s payment history or, in the case of a new customer, published credit and financial information pertaining to the customer. 2. Identify the performance obligations in the contract Performance obligations promised in a contract are identified based on the products or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the product or service either on its own or together with other resources that are readily available from the Company, and are distinct in the context of the contract, whereby the transfer of the products or services is separately identifiable from other promises in the contract. 3. Determine the transaction price The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. To the extent the transaction price is variable, revenue is recognized at an amount equal the consideration to which the Company expects to be entitled. This estimate includes customer sales incentives which are accounted for as a reduction to revenue and estimated using either the expected value method or the most likely amount method, depending on the nature of the program. As a result of the Company’s adoption of this standard, the majority of the amounts that were historically classified as bad debt expense, primarily related to self-payers customers, are now considered an implicit price concession in determining net revenue. Accordingly, the Company recognized uncollectible balances associated with self-payers customers as a reduction of the transaction price and therefore as a reduction in net revenues when historically these amounts were classified as bad debt expense within general and administrative expenses. Shipping and handling costs charged to customers are included in net sales. Determining the transaction price requires significant judgment, which is discussed by revenue category in further detail below. In practice, we do not offer extended payment terms beyond one year to customers. As such, we do not adjust our consideration for financing arrangements. 4. Allocate the transaction price to performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price basis unless a portion of the variable consideration related to the contract is allocated entirely to a performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. 5. Recognize revenue when or as the Company satisfies a performance obligation The Company generally satisfies performance obligations at a point in time, once the customer has obtained the legal title to the items purchased or service provided. For systems sold to rehabilitation facilities, the Company includes training and considers the elements in the arrangement to be a single performance obligation. In accordance with ASC 606, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed. For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery. Revenue is recognized based on the transaction price at the time the related performance obligation is satisfied by transferring a promised product or service to a customer. The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience. Disaggregation of Revenues Year Ended December 31, 2018 2017 (1) 2016 (1) Units placed 6,237 7,490 5,670 Spare parts and warranties 308 263 199 Total Revenues 6,545 7,753 5,869 (1) As noted above, prior period amounts have not been adjusted under the modified retrospective method. Units placed We currently offer two products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is currently designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides individuals access to valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal in the future. Units placed includes revenue from sales of a ReWalk Personal or ReWalk Rehabilitation. We also offer a Rent-to-Purchase model in which we recognize revenue ratably according to the agreed rental monthly fee. For units placed, we transfer control and recognize a sale when title has passed to our customer and rental revenue ratably according to the agreed rental monthly fee. Each unit placed is considered an independent, unbundled performance obligation. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. For spare part sales, we transfer control and recognize a sale when title has passed to our customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, we updated our service policy to include a five-year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. Contract balances December 31, December 31, 2018 2017 Trade receivable, net $ 758 $ 1,103 Short and Long term deferred revenues (1) $ 668 $ 384 (1) $135 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the year ended December 31, 2018. In addition to the above revenue recognition timing impacts, ASC 606 requires incremental contract acquisition costs (such as sales commissions) for customer contracts to be capitalized and amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the assets relates. Previously, these costs were expensed as incurred. Typical timing of payment The timing of satisfaction of our performance obligations does not significantly vary from the typical timing of payment. Typical payment terms are based on payment terms as established in our contracts. For some contracts we may be entitled to receive an advance payment. Transaction price allocated to remaining performance obligations for the year ended December 31, 2018, revenue recognized from performance obligations related to prior periods was not material. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material. The Company’s unfilled performance obligations as of December 31, 2018 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $676 thousand, which is fulfilled over one to five years.
Accounting for Share-Based Compensation	k. Accounting for Share-Based Compensation: The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation-Stock Compensation” (“ASC No. 718”). ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. Effective as of January 1, 2017, the Company adopted Accounting Standards Update 2016-09, “Compensation-Stock Compensation (Topic 718)” (“ASU 2016-09”) on a modified, retrospective basis. ASU 2016-09 permits entities to make an accounting policy election related to how forfeitures will impact the recognition of compensation cost for stock-based compensation: to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures as they occur. Upon adoption of ASU 2016-09, the Company elected to change its accounting policy to account for forfeitures as they occur. The change was applied on a modified, retrospective basis with a cumulative-effect adjustment to retained earnings of $11 thousand (which increased the accumulated deficit) as of January 1, 2017. ASU 2016-09 also eliminates the requirement that excess tax benefits be realized as a reduction in current taxes payable before the associated tax benefit can be recognized as an increase in paid in capital. The implementation resulted with no cumulative-effect adjustment to retained earnings as of January 1, 2017. Additionally, ASU 2016-09 addresses the presentation of excess tax benefits and employee taxes paid on the statement of cash flows. The Company is now required to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. The Company adopted this change prospectively. The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. Following the IPO in September 2014, the fair value of ordinary shares is observable as they are publicly traded. The fair value of Restricted Stock Units (RSUs) granted is determined based on the price of the Company’s ordinary shares on the date of grant. The fair value for options granted in 2018, 2017 and 2016 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions: December 31, 2018 2017 2016 Expected volatility 57% - 61 % 55% - 59 % 53% - 60 % Risk-free rate 2.74% - 2.83 % 1.78% - 2.07 % 1.16% - 1.60 % Dividend yield — % — % — % Expected term (in years) 6.11 5.31 - 6.11 5.31 - 6.11 Share price $ 1.02 - $1.15 $ 1.30 - $2.00 $ 6.80 - $11.88 The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model. The non-cash compensation expenses related to non-employees for the years ended December 31, 2018, 2017 amounted to $90 thousand and $45 thousand respectively, in 2016 the non-cash compensation expenses related to non-employees were immaterial. The non-cash compensation expenses related to employees and non- employees for the years ended December 31, 2018, 2017 and 2016 amounted to $2,766 thousand, $3,654 thousand and $3,398 thousand respectively.
Research and Development Costs	l. Research and Development Costs: Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants the company receive for research and development in the period in which the grant was received.
Income Taxes	m. Income Taxes The Company accounts for income taxes in accordance with ASC No. 740, “Income Taxes” (“ASC No. 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized. ASC No. 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income. As of December 31, 2018 and 2017, the Company did not identify any significant uncertain tax positions.
Warranty	n. Warranty: The Company provides a two-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in thousands Balance at December 31, 2017 $ 488 Provision 185 Usage (369 ) Balance at December 31, 2018 $ 304
Concentrations of Credit Risks	o. Concentrations of Credit Risks: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables. The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution. Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. December 31, 2018 2017 Customer A * ) 14 % Customer B * ) 17 % Customer C * ) 10 % Customer D 28 % * ) Customer E 15 % * ) Customer F 14 % * ) Customer G 13 % * ) Customer H 12 % * ) *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of December 31, 2018 and 2017 trade receivables are presented net of $32 thousand and $125 thousand allowance for doubtful accounts, respectively, and net of sales return reserve of $105 thousand.
Accrued Severance Pay	p. Accrued Severance Pay: Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet. Total Company expenses related to severance pay amounted to $169 thousand, $185 thousand and $226 thousand for the years ended December 31, 2018, 2017 and 2016, respectively.
Fair Value Measurements	q. Fair Value Measurements: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows: ● Level 1. ● Level 2. ● Level 3. The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.
Basic and Diluted Net Loss Per Share	r. Basic and Diluted Net Loss Per Share: Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of ordinary shares, including stock options, convertible preferred share warrants, to the extent dilutive, all in accordance with ASC No. 260, “Earning Per Share”. The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data): Year ended December 31 2018 2017 2016 Net loss $ (21,675 ) $ (24,717 ) $ (32,503 ) Net loss attributable to ordinary shares (21,675 ) (24,717 ) (32,503 ) Shares used in computing net loss per ordinary shares, basic and diluted 36,812,476 20,214,895 13,178,107 Net loss per ordinary share, basic and diluted $ (0.59 ) $ (1.22 ) $ (2.47 ) Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares outstanding would have been anti-dilutive.
Contingent liabilities	s. Contingent liabilities The Company accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. See note 7e for further information.
Government grants	t. Government grants Government grants received by the Company relating to categories of operating expenditures are credited to the consolidated statements of operations during the period in which the expenditure to which they relate is charged. Royalty and non-royalty-bearing grants from the Israel Innovation Authority, or the IIA, (formerly known as the Israeli Office of the Chief Scientist), from the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”) and from the Israeli Fund for Promoting Overseas Marketing for funding certain approved research and development projects and sales and marketing activities are recognized at the time when the Company is entitled to such grants, on the basis of the related costs incurred, and are included as a deduction from research and development or sales and marketing expenses (see Note 7c). The Company received royalty-bearing grants in the amount of $198 and $1,030 for the years ended December 31, 2018, 2017. No royalty-bearings grants were recorded for the year ended December 31, 2016, respectively, as part of the research and development expenses. The Company recorded no royalty expenses for the years ended December 31, 2018, 2017 and 2016, respectively, as part of the cost of revenues.
New Accounting Pronouncements	u. New Accounting Pronouncements Recently Implemented Accounting Pronouncements i. Revenues In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance, including industry-specific guidance. The core principle is that an entity will recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The standard provides a five-step model to be applied to all contracts with customers, which steps are to (1) identify the contract(s) with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when each performance obligation is satisfied. The Company adopted ASU 2014-09 as of the January 1, 2018 using the modified retrospective transition method with a cumulative-effect adjustment to equity. The adoption of this new standard may result in a change in the timing of revenue recognition related to certain of the company’s contracts. The most significant impact of the new standard relates to the way the Company accounts for cash-basis transactions, which will no longer be applicable under the new standard. The Company has implemented new processes and internal controls to enable the preparation of financial information on adoption. The adoption did not have a significant impact to the company’s net income. The cumulative impact to the company’s accumulated deficit as of January 1, 2018 is a reduction of $23 thousand, reflecting the accounting changes related to certain contracts made upon adoption of this new standard. The adoption of ASU 2014-09 has also resulted in additional disclosures around nature and timing of the Company’s performance obligations, deferred revenue contract liabilities, deferred contract cost assets, as well as significant judgments and practical expedients used by the Company in applying the five-step revenue model. ii. Share Based Compensation: On May 10, 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting.” This ASU clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. They will have to make all of the disclosures about modifications that are required today, in addition to disclosing that compensation expense has not changed, to the extent applicable. The ASU also clarifies that a modification to an award could be significant and therefore require disclosure, even if modification accounting is not required. The Company adopted ASU 2017-09 on January 1, 2018 and it did not have an impact on its accounting and disclosures. iii. Cash Flow: In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses several matters of diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows including the presentation of debt extinguishment costs and distributions received from equity method investments. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods and allows for retrospective adoption with early adoption permitted. The Company adopted ASU 2016-15 on January 1, 2018 and it did not have a material impact on its accounting and disclosures. On November 17, 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force) Recent Accounting Pronouncements Not Yet Adopted i. Leases: On February 25, 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Leases Leases (Topic 842): Targeted Improvements The Company determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Since our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company utilized a valuation specialist to determine the incremental borrowing rate as of December 31, 2018. Adoption of the standard is expected to have an impact of approximately $2.1 million on our consolidated balance sheets for the addition of lease assets and liabilities related to operating leases. ASU 2016-02 also requires expanded disclosure regarding the amounts, timing and uncertainties of cash flows related to a company’s lease portfolio. We are evaluating these disclosure requirements and are incorporating the collection of relevant data into our processes in preparation for disclosure in 2019. We do not expect ASU 2016-02 to have a material impact on our annual results of operations and/or cash flows.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of property and equipment estimated useful lives	% Computer equipment 20-33 (mainly 33) Office furniture and equipment 6 - 10 (mainly 10) Machinery and laboratory equipment 15 Field service units 50 Leasehold improvements Over the shorter of the lease
Schedule of disaggregation of revenues	Year Ended December 31, 2018 2017 (1) 2016 (1) Units placed 6,237 7,490 5,670 Spare parts and warranties 308 263 199 Total Revenues 6,545 7,753 5,869 (1) As noted above, prior period amounts have not been adjusted under the modified retrospective method.
Schedule of trade receivables and short and long term deferred revenues	December 31, December 31, 2018 2017 Trade receivable, net $ 758 $ 1,103 Short and Long term deferred revenues (1) $ 668 $ 384 (1) $135 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the year ended December 31, 2018.
Schedule of Black-Scholes-Merton option pricing model assumptions	December 31, 2018 2017 2016 Expected volatility 57% - 61 % 55% - 59 % 53% - 60 % Risk-free rate 2.74% - 2.83 % 1.78% - 2.07 % 1.16% - 1.60 % Dividend yield — % — % — % Expected term (in years) 6.11 5.31 - 6.11 5.31 - 6.11 Share price $ 1.02 - $1.15 $ 1.30 - $2.00 $ 6.80 - $11.88
Schedule of product warranty liability	US Dollars in thousands Balance at December 31, 2017 $ 488 Provision 185 Usage (369 ) Balance at December 31, 2018 $ 304
Schedule of concentration of credit risk	December 31, 2018 2017 Customer A * ) 14 % Customer B * ) 17 % Customer C * ) 10 % Customer D 28 % * ) Customer E 15 % * ) Customer F 14 % * ) Customer G 13 % * ) Customer H 12 % * ) *) Less than 10%
Schedule of basic and diluted net loss per ordinary share	Year ended December 31 2018 2017 2016 Net loss $ (21,675 ) $ (24,717 ) $ (32,503 ) Net loss attributable to ordinary shares (21,675 ) (24,717 ) (32,503 ) Shares used in computing net loss per ordinary shares, basic and diluted 36,812,476 20,214,895 13,178,107 Net loss per ordinary share, basic and diluted $ (0.59 ) $ (1.22 ) $ (2.47 )

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	December 31, 2018 2017 Government institutions $ 167 $ 191 Prepaid expenses 155 342 Advances to vendors 371 634 Other assets — 458 $ 693 $ 1,625

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of components of inventories	December 31, 2018 2017 Finished products $ 2,240 $ 3,643 $ 2,240 $ 3,643

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of components of Property and Equipment, Net	December 31, 2018 2017 Cost: Computer equipment $ 712 $ 709 Office furniture and equipment 293 293 Machinery and laboratory equipment 593 583 Field service units 1,246 1,010 Leasehold improvements 333 333 $ 3,177 $ 2,928 December 31, 2018 2017 Accumulated depreciation 2,551 2,088 Property and equipment, net $ 626 $ 840

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease commitments	2019 545 2020 544 2021 553 2022 562 2023 438 And Thereafter — Total $ 2,642

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of employee share options and RSUs activity	Number Average exercise price Average remaining contractual life (years) Aggregate intrinsic value (in thousands) Options outstanding at the beginning of the year 1,277,726 $ 2.69 6.33 $ 8 Granted 662,427 1.09 Exercised — — Forfeited (122,894 ) 5.54 Options outstanding at the end of the year 1,817,259 $ 1.91 6.37 $ — Options exercisable at the end of the year 1,033,602 $ 2.39 4.25 $ —
Summary of employee RSUs activity	Number of shares underlying outstanding RSUs Weighted- average grant date fair value Unvested RSUs at the beginning of the year 569,071 3.13 Granted 510,803 1.09 Vested (1) (342,820 ) 2.74 Forfeited (84,304 ) 2.59 Unvested RSUs at the end of the year 652,750 1.80 (1) During the fiscal year ended December 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested on a net basis was 340,367 ordinary shares.
Schedule of options and RSUs outstanding	Range of exercise price Options and RSUs Outstanding as of December 31, 2018 Weighted average remaining contractual life (years) (1) Options Exercisable as of December 31, 2018 Weighted average remaining contractual life (years) (1) RSUs only 652,750 — — — $0.82 19,764 2.03 19,764 2.03 $1.32 980,355 7.38 322,928 3.42 $1.47-$2.10 718,800 5.04 597,093 4.35 $6.80-$8.99 66,941 7.05 63,000 7.06 $9.22-$10.98 14,046 7.32 13,577 7.33 $19.62-$20.97 17,353 5.97 17,240 5.97 2,470,009 6.37 1,033,602 4.25 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of warrants outstanding and exercisable	Issuance date Warrants outstanding Exercise price per warrant Warrants exercisable Exercisable through (number) (number) December 30, 2015 (1) (4) 119,295 $ 0.30 119,295 See footnote (1) November 1, 2016 (2) 2,437,500 $ 4.75 2,437,500 November 1, 2021 December 28, 2016 (3) (4) 47,717 $ 0.3 47,717 See footnote (1) November 20, 2018 (5) 44,459,830 $ 0.3 44,459,830 November 20, 2023. November 20, 2018 (6) 2,667,590 $ 0.375 2,667,590 November 15, 2023 November 20, 2018 (7) 9,930,382 $ 0.01 9,930,382 November 20, 2023. 59,662,314 59,662,314 (1) Represents warrants for ordinary shares issuable upon an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2018. (2) Represents warrants issued as part of our follow-on offering in November 2016. The exercise price and the number of ordinary shares into which the warrants may be exercised are subject to adjustment upon certain corporate events, including stock splits, reverse stock splits, combinations, stock dividends, recapitalizations, reorganizations and certain other events. Our board of directors may also determine to make such adjustments to the exercise price and number of ordinary shares to be issued upon exercise based on similar events, including the granting of stock appreciation rights, phantom stock rights or other rights with equity features. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (3) Represents warrants in the amount of 47,717 ordinary shares that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (4) On November 20, 2018, Kreos and the Company entered into the First Amendment to the Warrant to Purchase Shares (the “Kreos Warrant Amendment”), which amended the exercise price of the warrant to purchase 167,012 ordinary shares currently held by Kreos from $9.64 to $0.30. See note 6. (5) Represents warrants in the amount of 44,459,830 ordinary shares that were issued as part of our follow-on offering in November 2018. (6) Represents warrants to purchase up to 2,667,590 ordinary shares that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018. (7) Represents 26,259,332 pre-funded warrants with an exercise price of $0.01 per share. As of December 31, 2018, pre-funded warrants to purchase an aggregate 16,328,950 ordinary shares had been exercised.
Schedule of non-cash share-based compensation expense	Year Ended December 31, 2018 2017 2016 Cost of revenues $ 16 $ 62 $ 108 Research and development, net 435 508 559 Sales and marketing, net 467 963 811 General and administrative 1,848 2,121 1,920 Total $ 2,766 $ 3,654 $ 3,398

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of loss before taxes on income	Year Ended December 31, 2018 2017 2016 Domestic $ (21,784 ) $ (24,728 ) $ (32,642 ) Foreign 104 130 142 $ (21,680 ) $ (24,598 ) $ (32,500 )
Schedule of taxes on income	Year Ended December 31, 2018 2017 2016 Current $ 102 $ 46 $ 8 Deferred (107 ) 73 (5 ) $ (5 ) $ 119 $ 3 Year Ended December 31, 2018 2017 2016 Domestic $ — $ — $ — Foreign (5 ) 119 3 $ (5 ) $ 119 $ 3
Schedule of deferred income taxes	December 31, 2018 2017 Carry forward tax losses $ 28,033 $ 24,969 Research and development carry forward expenses-temporary differences 1,567 1,282 Accrual and reserves 241 139 Deferred tax assets before valuation allowance 29,841 26,390 Valuation allowance (29,655 ) (26,311 ) Net deferred tax assets $ 186 $ 79
Schedule of net changes in total valuation allowance	Year Ended December 31, 2018 2017 2016 Balance at beginning of year $ (26,311 ) $ (22,560 ) $ (16,196 ) Changes due to amendments to tax laws and exchange rate differences 1,393 1,806 917,000 Adjustment previous year loss — (591 ) — Additions during the year (4,737 ) (4,966 ) (7,281 ) Balance at end of year $ (29,655 ) $ (26,311 ) $ (22,560 )
Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit)	Year Ended December 31, 2018 2017 2016 Loss before taxes, as reported in the consolidated statements of operations $ (21,680 ) $ (24,598 ) $ (32,500 ) Statutory tax rate 23.0 % 24.0 % 25.0 % Theoretical tax benefits on the above amount at the Israeli statutory tax rate $ (4,986 ) $ (5,904 ) $ (8,125 ) Income tax at rate other than the Israeli statutory tax rate 5 17 10 Non-deductible expenses including equity based compensation expenses and other 631 878 857 Operating losses and other temporary differences for which valuation allowance was provided 4,737 4,966 7,281 Other (392 ) 162 (20 ) Actual tax expense $ (5 ) $ 119 $ 3

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Other Income and Expenses [Abstract]
Schedule of financial expenses, net	Year Ended December 31, 2018 2017 2016 Foreign currency transactions and other $ 42 $ (188 ) $ 85 Financial expenses related to loan agreement with Kreos 2,398 2,451 1,976 Bank commissions 26 30 34 Income related to hedging transactions — — (36 ) $ 2,466 $ 2,293 $ 2,059

Geographic Information and Ma_2

Geographic Information and Major Customer and Product Data (Tables)	12 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	Year Ended December 31, 2018 2017 2016 Revenues based on customer’s location: Israel $ — $ — $ — United States 3,558 4,598 3,741 Europe 2,807 3,094 1,144 Asia-Pacific 22 61 984 Latin America 58 — — Africa 100 — — Total revenues $ 6,545 $ 7,753 $ 5,869
Schedule of long-lived assets by geographic region	December 31, 2018 2017 Long-lived assets by geographic region: Israel $ 206 $ 298 United States 330 342 Germany 90 200 $ 626 $ 840 (*) Long-lived assets are comprised of property and equipment, net.
Schedule of major customer data as a percentage of total revenues	Year Ended December 31, 2018 2017 2016 Customer A 38.0 % 35.2 % 33.3 %

General (Details)

General (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2018	Nov. 20, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	May 10, 2016
General (Textual)
Accumulated deficit			$ (152,918)	$ (131,220)
Negative cash flow from operations			$ (14,774)	$ (22,462)	$ (26,747)
Kreos [Member] | Second Amendment [Member]
General (Textual)
Agreed to pay outstanding indebtedness		$ 3,600
Proceeds of public offering		$ 3,600
Number of purchasing units		4,800,000
Number of pre-funded units		7,200,000
Aggregate price of public offering		$ 3,600
Exercise price of warrant to purchase ordinary shares		167,012
Kreos [Member] | Second Amendment [Member] | Minimum [Member]
General (Textual)
Exercise price of warrant to purchase ordinary shares per share		$ 0.30
Kreos [Member] | Second Amendment [Member] | Maximum [Member]
General (Textual)
Exercise price of warrant to purchase ordinary shares per share		$ 9.64
ATM Offering Program [Member]
General (Textual)
Number of shares issued and sold			1,247,172
Average price			$ 1.09
Gross proceeds amount			$ 1,400
Aggregate amount of fees and offering expenses			1,100
Aggregate amount of fees			236
Maximum amount which can be raised under ATM offering program			$ 25,000			$ 25,000
Follow-on public offering [Member]
General (Textual)
Number of shares issued and sold	18,200,498
Gross proceeds amount	$ 13,100
Description of follow-on public offering	The Company completed its follow-on public offering in which the Company issued and sold 18,200,498 units, each consisting of one ordinary share and one warrant to purchase one ordinary share. Each unit was sold to the public at a price of $0.30 per unit, additionally the company issued and sold 26,259,332 pre-funded units, each unit was sold to the public at a price of $0.29 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.01 per share and one warrant to purchase one ordinary share. The total gross proceeds received from the follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million. (including proceeds from the exercise of 2,267,284 pre-funded warrants at the closing of the offering).
Public price per unit	$ 0.30
Additionally issued and sold pre-funded units	26,259,332
Additionally issued and sold public price per unit	$ 0.29
Proceeds from exercise of pre-funded warrants	2,267,284
Additional pre-funded warrants to purchase aggregate ordinary shares exercised			14,061,666
Additional proceeds of pre-funded warrants			$ 140,617
Underwriters warrants to purchase ordinary shares issued			2,667,590
Underwriters warrants to purchase exercisable term			November 20, 2018 until November 15, 2023
Underwriters warrants to purchase exercisable price per share			$ 0.375

Significant Accounting Polici_4

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2018
Computer equipment [Member] | Minimum [Member]
Property and equipment estimated useful lives	20%
Computer equipment [Member] | Maximum [Member]
Property and equipment estimated useful lives	33%
Office furniture and equipment [Member] | Minimum [Member]
Property and equipment estimated useful lives	6%
Office furniture and equipment [Member] | Maximum [Member]
Property and equipment estimated useful lives	10%
Machinery and laboratory equipment [Member]
Property and equipment estimated useful lives	15%
Field service units [Member]
Property and equipment estimated useful lives	50%
Leasehold improvements [Member]
Property and equipment estimated useful lives	Over the shorter of the lease term or estimated useful life

Significant Accounting Polici_5

Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	[1]	Dec. 31, 2016	[1]
Total Revenues	$ 6,545	$ 7,753		$ 5,869
Units placed [Member]
Total Revenues	6,237	7,490		5,670
Spare parts and warranties [Member]
Total Revenues	$ 308	$ 263		$ 199
[1]	As noted above, prior period amounts have not been adjusted under the modified retrospective method.

Significant Accounting Polici_6

Significant Accounting Policies (Details 2) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Trade receivable, net		$ 758	$ 1,103
Short and Long term deferred revenues	[1]	$ 668	$ 384
[1]	$135 thousand of December 31, 2017 deferred revenues balance were recognized as revenues during the year ended December 31, 2018.

Significant Accounting Polici_7

Significant Accounting Policies (Details 3) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield
Expected term (in years)	6 years 1 month 9 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	57.00%	55.00%	53.00%
Risk-free rate	2.74%	1.78%	1.16%
Expected term (in years)		5 years 3 months 22 days	5 years 3 months 22 days
Share price	$ 1.02	$ 1.30	$ 6.80
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	61.00%	59.00%	60.00%
Risk-free rate	2.83%	2.07%	1.60%
Expected term (in years)		6 years 1 month 9 days	6 years 1 month 9 days
Share price	$ 1.15	$ 2	$ 11.88

Significant Accounting Polici_8

Significant Accounting Policies (Details 4) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Warranty provision:
Balance at December 31, 2017	$ 488
Provision	185
Usage	(369)
Balance at December 31, 2018	$ 304

Significant Accounting Polici_9

Significant Accounting Policies (Details 5)	12 Months Ended
	Dec. 31, 2018		Dec. 31, 2017
Customer A [Member]
Concentration of credit risk		[1]	14.00%
Customer B [Member]
Concentration of credit risk		[1]	17.00%
Customer C [Member]
Concentration of credit risk		[1]	10.00%
Customer D [Member]
Concentration of credit risk	28.00%			[1]
Customer E [Member]
Concentration of credit risk	15.00%			[1]
Customer F [Member]
Concentration of credit risk	14.00%			[1]
Customer G [Member]
Concentration of credit risk	13.00%			[1]
Customer H [Member]
Concentration of credit risk	12.00%			[1]
[1]	Less than 10%

Significant Accounting Polic_10

Significant Accounting Policies (Details 6) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Net loss	$ (21,675)	$ (24,717)	$ (32,503)
Net loss attributable to ordinary shares	$ (21,675)	$ (24,717)	$ (32,503)
Shares used in computing net loss per ordinary shares, basic and diluted	36,812,476	20,214,895	13,178,107
Net loss per ordinary share, basic and diluted	$ (0.59)	$ (1.22)	$ (2.47)

Significant Accounting Polic_11

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Significant Accounting Policies (Textual)
Wrote off inventory amount	$ 562	$ 131	$ 237
Impairment losses
Allowance for doubtful accounts	32	125
Net of sales return reserve	$ 105	105
Deferred revenue recognized		135
Revenue recognition description	The estimated revenue expected to be recognized in the future related to the service type warranty amounts to $676 thousand, which is fulfilled over one to five years.
Maximum percentage of likely to be realized upon ultimate settlement	50%
Percentage of monthly deposit by employees	8.33%
Severance pay expense	$ 169	185	226
Royalty-bearing grants expenses	198	1,030
Royalty expenses
Addition of lease assets and liabilities related to operating leases	2,100
Non-employees [Member]
Significant Accounting Policies (Textual)
Non-cash compensation expenses	90	45
Employees and non- employees [Member]
Significant Accounting Policies (Textual)
Non-cash compensation expenses	$ 2,766	3,654	3,398
Accounting Standards Update 2016-09 [Member]
Significant Accounting Policies (Textual)
Cumulative-effect adjustment to retained earnings/accumulated deficit			11
Accounting Standards Update 2014-09 [Member]
Significant Accounting Policies (Textual)
Cumulative-effect adjustment to retained earnings/accumulated deficit		$ 23
YEC [Member]
Significant Accounting Policies (Textual)
Related party receivables as a percent of trade receivables, net	0.00%	0.00%
Revenues from related party	$ 13	$ 0	$ 295

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Government institutions	$ 167	$ 191
Prepaid expenses	155	342
Advances to vendors	371	634
Other assets		458
Prepaid expenses and other current assets	$ 693	$ 1,625

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished products	$ 2,240	$ 3,643
Inventories	$ 2,240	$ 3,643

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 3,177	$ 2,928
Accumulated depreciation	2,551	2,088
Property and equipment, net	626	840
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	712	709
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	293	293
Machinery and laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	593	583
Field service units [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,246	1,010
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 333	$ 333

Property and Equipment, Net (_2

Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property and Equipment, Net (Textual)
Depreciation expenses	$ 463	$ 642	$ 696

Loan Agreement with Kreos and_2

Loan Agreement with Kreos and Related Warrant to Purchase Ordinary Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 09, 2017	Dec. 30, 2015	Nov. 20, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Loan Agreement with Kreos and Related Warrant to Purchase Ordinary Shares (Textual)
Proceeds from long term loan						$ 20,000
Loss on extinguishment of debt					$ 313
Convertible note				300
Finance expenses				$ 672
Secured Debt [Member]
Loan Agreement with Kreos and Related Warrant to Purchase Ordinary Shares (Textual)
Proceeds from long term loan		$ 20,000
Loan term		36 months
Annual interest rate		10.75%
Extended repayment term		36 months
Required proceeds from issuance of common stock required for repayment period to be extended		$ 20,000
Loan term initial period		24 months
Loan Amendment [Member] | Secured Debt [Member]
Loan Agreement with Kreos and Related Warrant to Purchase Ordinary Shares (Textual)
Proceeds from long term loan	$ 20,000
Extended repayment term	3 years
Outstanding principal	$ 17,200
Portion of principal subject to repayment extension	$ 3,000
Convertible debt, number of shares that may be converted (in shares)	2,523,660
Conversion price (in USD per share)	$ 1.268
Convertible debt, amount that principal may be reduced	$ 3,000
Outstanding principal not subject to conversion	14,200
End of loan payments	$ 200
End of loan payments, number of shares that may be converted (up to)	157,729
Loss on extinguishment of debt	$ 313
Loan agreement repayment terms, description	The repayment period will be extended to 36 months if the Company raises $20 million or more in connection with the issuance of shares of its capital stock (including debt securities convertible into shares of the Company’s capital stock). As of June 30, 2017 the Company had raised more than $20 million and therefore the repayment period was extended by an additional 12 months to 36 months.
Second Amendment [Member]
Loan Agreement with Kreos and Related Warrant to Purchase Ordinary Shares (Textual)
Interest payments, description			On November 20, 2018, the Company and Kreos entered into the Second Amendment of the Loan Agreement (the ''Second Amendment''). In the Second Amendment, the Company agreed to repay $3.6 million to Kreos in satisfaction of all outstanding indebtedness under the Kreos Convertible Note and other related payments, including prepayment costs and ''end of loan payments'', and Kreos agreed to terminate the Kreos Convertible Note. The Company paid Kreos the $3.6 million by issuing to Kreos 4,800,000 units and 7,200,000 pre-funded units at the applicable public offering prices for an aggregate price of $3.6 million (including the aggregate exercise price for the ordinary shares to be received upon exercise of the pre-funded warrants, assuming Kreos exercises all of the pre-funded warrants it purchased) as part of the Company's public offering. The Company and Kreos also agreed to revise the principal and the repayment schedule under the Kreos Loan Agreement. Additionally, Kreos and the Company entered into the First Amendment to the Warrant to Purchase Shares (the ''Kreos Warrant Amendment''), which amended the exercise price of the warrant to purchase 167,012 ordinary shares currently held by Kreos from $9.64 to $0.30. The revised repayment schedule, effectively deferred an additional $1.1 million of payments that were due in 2018 and $2.8 million that were due in 2019 under the loan’s prior repayment schedule, for total deferred payments of $3.9 million compared to the prior repayment schedule. The loan repayment schedule was extended for a period of three months. As of December 31, 2018, the outstanding principal amount under the Kreos Loan Agreement was $8.7 million. The Second Amendment also made certain changes to the prepayment premiums under the Kreos Loan Agreement, tying them to the date of the Second Amendment. Under ASC 470-50 a modification treatment is applicable. The warrants amended exercise price was treated under ASC 470-50-10 as modification and therefore were capitalized and will be amortized as part of the effective yield.

Commitments and Contingent Li_3

Commitments and Contingent Liabilities (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 545
2,020	544
2,021	553
2,022	562
2,023	438
And Thereafter
Total	$ 2,642

Commitments and Contingent Li_4

Commitments and Contingent Liabilities (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Commitments and Contingent Liabilities (Textual)
Non-cancelable outstanding obligations	$ 350
Maximum penalties payable on early release of agreement	39
Total fund received	1,970
Royalties expenses
Lease expiration, term	These leases expire between 2019 and 2023.
Other long-term assets	$ 801
Rent expenses	$ 695	$ 682	$ 650
Initial public offering [Member]
Commitments and Contingent Liabilities (Textual)
Description of conversion ratio	Ordinary shares in a conversion ratio of 1 to 1.
IIA [Member]
Commitments and Contingent Liabilities (Textual)
Royalty bearing grants	$ 1,570
Royalties paid	50
Contingent liability	$ 1,500
Percentage of grant received	100.00%
IIA [Member] | Minimum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties	3.00%
IIA [Member] | Maximum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties	3.50%
IIA [Member] | Series A Preferred Stock [Member]
Commitments and Contingent Liabilities (Textual)
Amount received in consideration of preferred shares	$ 400
Convertible preferred shares	5,237
BIRD [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received	$ 500
Percentage of obligation to pay royalties	5.00%
BIRD [Member] | Maximum [Member]
Commitments and Contingent Liabilities (Textual)
Percentage of obligation to pay royalties	150.00%
RRL [Member]
Commitments and Contingent Liabilities (Textual)
Lease expiration, term	RRL lease cars for its employees under cancelable operating lease agreements expiring at various dates in 2019-2021.

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Employee Stock Option and Restricted Stock Units RSUs [Member] - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Number
Options outstanding at the beginning of the year		1,277,726
Options granted		662,427
Options exercised	[1]
Options forfeited		(122,894)
Options outstanding at the end of the year		1,817,259	1,277,726
Options exercisable at the end of the period		1,033,602
Average exercise price
Options outstanding at the beginning of the year		$ 2.69
Options granted		1.09
Options exercised	[1]
Options forfeited		5.54
Options outstanding at the end of the year		1.91	$ 2.69
Options exercisable at the end of the period		$ 2.39
Average remaining contractual life (in years)
Options outstanding	[2]	6 years 4 months 13 days	6 years 3 months 29 days
Options exercisable at the end of the period	[2]	4 years 2 months 30 days
Aggregate intrinsic value (in thousands)
Options outstanding at the beginning of the year		$ 8
Options outstanding at the end of the year			$ 8
Options exercisable at the end of the period
[1]	During the fiscal year ended December 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 340,367 ordinary shares.
[2]	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Unvested RSUs at the beginning of the year | shares	569,071
Granted | shares	510,803
Vested | shares	(342,820)	[1]
Forfeited | shares	(84,304)
Unvested RSUs at the end of the year | shares	652,750
Weighted-average grant date fair value, Unvested RSUs at the beginning of the year | $ / shares	$ 3.13
Granted | $ / shares	1.09
Vested | $ / shares	2.74	[1]
Forfeited | $ / shares	2.59
Weighted-average grant date fair value, Unvested RSUs at the end of the year | $ / shares	$ 1.80
[1]	During the fiscal year ended December 31, 2018, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested on a net basis was 340,367 ordinary shares.

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - $ / shares		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Employee Stock Option [Member] | Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price		$ 0.82
Options outstanding		19,764
Options outstanding weighted average remaining contractual life (years)	[1]	2 years 11 days
Options exercisable		19,764
Options exercisable weighted average remaining contractual life (years)	[1]	2 years 11 days
Employee Stock Option [Member] | Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price		$ 1.32
Options outstanding		980,355
Options outstanding weighted average remaining contractual life (years)	[1]	7 years 4 months 17 days
Options exercisable		322,928
Options exercisable weighted average remaining contractual life (years)	[1]	3 years 5 months 1 day
Employee Stock Option [Member] | Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum		$ 1.47
Range of exercise price, maximum		$ 2.10
Options outstanding		718,800
Options outstanding weighted average remaining contractual life (years)	[1]	5 years 15 days
Options exercisable		597,093
Options exercisable weighted average remaining contractual life (years)	[1]	4 years 4 months 6 days
Employee Stock Option [Member] | Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum		$ 6.80
Range of exercise price, maximum		$ 8.99
Options outstanding		66,941
Options outstanding weighted average remaining contractual life (years)	[1]	7 years 18 days
Options exercisable		63,000
Options exercisable weighted average remaining contractual life (years)	[1]	7 years 22 days
Employee Stock Option [Member] | Exercise Price Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum		$ 9.22
Range of exercise price, maximum		$ 10.98
Options outstanding		14,046
Options outstanding weighted average remaining contractual life (years)	[1]	7 years 3 months 26 days
Options exercisable		13,577
Options exercisable weighted average remaining contractual life (years)	[1]	7 years 3 months 29 days
Employee Stock Option [Member] | Exercise Price Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, minimum		$ 19.62
Range of exercise price, maximum		$ 20.97
Options outstanding		17,353
Options outstanding weighted average remaining contractual life (years)	[1]	5 years 11 months 19 days
Options exercisable		17,240
Options exercisable weighted average remaining contractual life (years)	[1]	5 years 11 months 19 days
Employee Stock Option and Restricted Stock Units Rsus [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding weighted average remaining contractual life (years)	[1]	6 years 4 months 13 days
Options exercisable		1,033,602
Options exercisable weighted average remaining contractual life (years)	[1]	4 years 2 months 30 days
Options and RSUs outstanding		1,817,259	1,277,726
Restricted Stock Units (RSUs) [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
RSUs outstanding		652,750
Options and RSUs outstanding		569,071
[1]	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3) - $ / shares		12 Months Ended
		Dec. 31, 2018	Nov. 30, 2018
Class of Warrant or Right [Line Items]
Warrants outstanding		59,662,314
Exercise price per warrant			$ 0.30
Warrants exercisable		59,662,314
December 30, 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	[1]	119,295
Exercise price per warrant	[2],[3]	$ 0.30
Warrants exercisable	[1]	119,295
November 1, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	[4]	2,437,500
Exercise price per warrant	[4]	$ 4.75
Warrants exercisable	[4]	2,437,500
Warrants term	[4]	Nov. 1, 2021
December 28, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	[2],[5]	47,717
Exercise price per warrant	[2],[5]	$ 0.3
Warrants exercisable	[2],[5]	47,717
November 20, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	[6]	44,459,830
Exercise price per warrant	[6]	$ 0.3
Warrants exercisable	[6]	44,459,830
Warrants term	[6]	Nov. 20, 2023
November 20, 2018 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	[7]	2,667,590
Exercise price per warrant	[7]	$ 0.375
Warrants exercisable	[7]	2,667,590
Warrants term	[7]	Nov. 15, 2023
November 20, 2018 Two [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	[8]	9,930,382
Exercise price per warrant	[8]	$ 0.01
Warrants exercisable	[8]	9,930,382
Warrants term	[8]	Nov. 20, 2023
[1]	Represents warrants for ordinary shares issuable upon an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2018.
[2]	On November 20, 2018, Kreos and the Company entered into the First Amendment to the Warrant to Purchase Shares (the "Kreos Warrant Amendment"), which amended the exercise price of the warrant to purchase 167,012 ordinary shares currently held by Kreos from $9.64 to $0.30.
[3]	Represents warrants issuable upon the exercise of warrants to purchase ordinary shares at an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2018.
[4]	Represents warrants issued as part of our follow-on offering in November 2016. The exercise price and the number of ordinary shares into which the warrants may be exercised are subject to adjustment upon certain corporate events, including stock splits, reverse stock splits, combinations, stock dividends, recapitalizations, reorganizations and certain other events. Our board of directors may also determine to make such adjustments to the exercise price and number of ordinary shares to be issued upon exercise based on similar events, including the granting of stock appreciation rights, phantom stock rights or other rights with equity features. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate.
[5]	Represents warrants in the amount of 47,717 ordinary shares that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
[6]	Represents warrants in the amount of 44,459,830 ordinary shares that were issued as part of our follow-on offering in November 2018.
[7]	Represents warrants to purchase up to 2,667,590 ordinary shares that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018.
[8]	Represents 26,259,332 pre-funded warrants with an exercise price of $0.01 per share. As of December 31, 2018, pre-funded warrants to purchase an aggregate 16,328,950 ordinary shares had been exercised.

Shareholders' Equity (Details 4

Shareholders' Equity (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	$ 2,766	$ 3,654	$ 3,398
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	16	62	108
Research and development, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	435	508	559
Sales and marketing, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	467	963	811
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Non-cash share-based compensation expense	$ 1,848	$ 2,121	$ 1,920

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual) - USD ($)

May 15, 2018

Sep. 06, 2017

Dec. 28, 2016

May 10, 2016

Dec. 31, 2015

Nov. 30, 2018

Nov. 20, 2018

Nov. 18, 2018

May 31, 2018

Mar. 06, 2018

Nov. 30, 2017

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Shareholders' Equity (Textual)

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

$ 4,099,000

Shares reserved for future issuance (in shares)

1,535,634

1,301,521

Exercise price per share

$ 0.30

Expected term of shares

6 years 1 month 9 days

Sale of stock price per share

$ 0.08

Fixed commission rate

3.00%

Warrants to purchase ordinary shares

16,328,950

Minimum [Member]

Shareholders' Equity (Textual)

Expected term of shares

5 years 3 months 22 days

5 years 3 months 22 days

Equity Exchange Program [Member]

Shareholders' Equity (Textual)

Compensation payment

$ 159,000

Description of equity exchange program

On the Equity Exchange Program’s expiration date of October 4, 2017, 46 holders tendered options to purchase an aggregate of 945,416 ordinary shares, representing 96.4% of all options eligible for exchange, and on October 5, 2017, the Company granted to these holders an aggregate of 251,872 new RSUs. 180,167 of these new RSUs were granted to the Company’s executive officers and “named executive officers”

Canacord Gunuity Inc [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares (in shares)

117,891

RSUs held by non-employee consultants [Member]

Shareholders' Equity (Textual)

RSUs granted (in shares)

89,148

Options granted (in shares)

3,454

ATM Offering Program [Member]

Shareholders' Equity (Textual)

Aggregate offering price

$ 25,000,000

$ 25,000,000

Stock issuance costs under equity distribution agreement as a percent of gross proceeds

3.00%

3.00%

Price per share of shares sold under ATM offering program (in USD per share)

$ 1.09

Issuance of ordinary shares in an ATM offering of ordinary shares, gross of issuance expenses

$ 1,400,000

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

236,000

Issuance expenses

$ 211,000

Sale of ordinary shares

1,247,172

Proceeds percentage of sale of the ordinary shares

8.00%

Limitation on sales, description

The Company may raise up to $25 million under its ATM Offering Program pursuant to the terms of its agreement with the sales agent. However, due to limitations under the rules of Form S-3, which have applied to the Company since it filed its annual report on Form 10-K, in February 2017, as of the date of this annual report we may only issue up to approximately $13.7 million in primary offerings under our effective registration statement on Form S-3 (the "Form S-3"), including our ATM Offering Program, during any 12-month period while we remain subject to these limitations. Because we have already sold $15.7 million in the ATM Offering Program since its inception, we may only raise up to a remaining $9.3 million using the program, subject to the $13.7 million cap during any rolling 12-month period.

Gross proceeds amount

$ 1,400,000

ATM Offering Program One [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses

14,500,000

Issuance expenses

$ 1,171,000

Sale of ordinary shares

7,552,318

Compensation payment

$ 471,000

Gross proceeds

15,700,000

ATM Offering Program One [Member] | Minimum [Member]

Shareholders' Equity (Textual)

Issuance expenses

$ 1,100,000

Follow-on public offering [Member]

Shareholders' Equity (Textual)

Gross proceeds

$ 8,300,000

Additionally issued and sold pre-funded units

26,259,332

Description of follow-on public offering

The Company completed its follow-on public offering in which the Company issued and sold 18,200,498 units, each consisting of one ordinary share and one warrant to purchase one ordinary share. Each unit was sold to the public at a price of $0.30 per unit, additionally the company issued and sold 26,259,332 pre-funded units, each unit was sold to the public at a price of $0.29 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.01 per share and one warrant to purchase one ordinary share. The total gross proceeds received from the follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million. (including proceeds from the exercise of 2,267,284 pre-funded warrants at the closing of the offering).

Additionally issued and sold public price per unit

$ 0.29

Gross proceeds amount

$ 13,100,000

Proceeds from exercise of pre-funded warrants

2,267,284

Additional pre-funded warrants to purchase aggregate ordinary shares exercised

14,061,666

Additional proceeds of pre-funded warrants

$ 140,617,000

Underwriters warrants to purchase ordinary shares issued

2,667,590

Underwriters warrants to purchase exercisable term

November 20, 2018 until November 15, 2023

Underwriters warrants to purchase exercisable price per share

$ 0.375

Warrants to purchase ordinary shares

44,459,830

Underwriting agreement, description

The Company entered into the Underwriting Agreement with National Securities Corporation ("National"), in connection with the Company's follow-on public offering of 6,857,000 ordinary shares. Each ordinary share was sold to the public at a price of $1.05 per share. On November 22, 2017 National exercised in full its option to purchase 1,028,550 additional ordinary shares at the public offering price of $1.05 per share, less the underwriting discount.

Commission expenses

$ 7,200,000

Restricted Stock Units (RSUs) [Member]

Shareholders' Equity (Textual)

Weighted average grant date fair value, restricted stock units (in USD per share)

$ 9.28

$ 1.44

$ 9.28

Weighted average grant date fair value, options (in USD per share)

$ 1.02

$ 4.75

Total intrinsic value of options exercised

$ 340,367,000

$ 29,000

$ 844,000

Share option plan [Member]

Shareholders' Equity (Textual)

Total fair value of shares vested

2,918

3,785

3,626

Award vesting period, description

The options generally vest over four year, with certain options granted to non-employee directors during the fiscal year ended December 31, 2018, vesting over one year.

Shares reserved for future issuance (in shares)

1,301,521

Unrecognized cost of shares

$ 1,900,000

Expected term of shares

2 years

Timwell investment agreement [Member]

Shareholders' Equity (Textual)

Gross proceeds

$ 20,000,000

Fees and other related expenses

705,000

Net aggregate proceeds of after deducting fees and other related expenses

$ 4,300,000

Description of tranche consisting

The Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the closing of the First Tranche of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the closing of the first tranche of the Timwell transaction in May 15, 2018, the Company issued 117,891 ordinary shares to Canaccord Genuity.

The Company entered into an investment agreement with Timwell Corporation Limited, a Hong Kong corporation ("Timwell"), as amended on May 15, 2018 (the "Investment Agreement"), pursuant to which the Company agreed to issue to Timwell, in three different tranches, an aggregate of 16,000,000 ordinary shares in return for aggregate gross proceeds of $20 million. The closing of each tranche is subject to certain closing conditions. The closing of the first tranche (the "First Tranche Closing") took place on May 15, 2018, upon which Timwell received 4,000,000 ordinary shares for an aggregate purchase price of $5,000,000, and Timwell and the Company signed a registration rights agreement in the form attached to the Investment Agreement. The net aggregate proceeds of the First Tranche Closing after deducting fees and other related expenses in the amount of approximately $705 thousands were approximately $4.3 million. The remaining investment is to occur in two tranches, including $10 million for the issuance to Timwell of 8,000,000 ordinary shares (the "Second Tranche") and $5 million for the issuance to Timwell of 4,000,000 ordinary shares (the "Third Tranch"). The closing of the second and third tranches is subject to specified closing conditions, including, with respect to the second tranche, the signing of a license agreement and a supply agreement and the formation of the China JV (the "China JV") based on the JV Framework Agreement, and, with respect to the third tranche, the successful production of certain ReWalk products by the China JV. The second tranche closing was initially expected to occur by July 1, 2018 and the third tranche closing was initially expected to occur by December 31, 2018 and no later than April 1, 2019.

Kreos Capital [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares (in shares)

47,717

Exercise price per share

$ 9.64

Warrants exercisable, description

Currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.

Drawdown amount under loan agreement

$ 8,000,000

Warrants to purchase ordinary shares

167,012

H.C. wainwright [Member] | Follow-on public offering [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares (in shares)

5,799,108

Sale of stock price per share

$ 0.30

Additionally issued and sold pre-funded units

5,799,108

Additionally issued and sold public price per unit

$ 0.29

Underwriters warrants to purchase ordinary shares issued

12,401,390

Underwriters warrants to purchase exercisable price per share

$ 0.01

Research Collaboration Agreem_2

Research Collaboration Agreement and License Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Research Collaboration Agreement and License Agreement (Textual)
Research and development expenses	$ 7,349	$ 6,042	$ 9,028
Harvard License Agreement and Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Total payment obligation	6,500
Research and development expenses	$ 900
Research collaboration agreement expire date	May 16, 2021

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes Details Abstract
Domestic	$ (21,784)	$ (24,728)	$ (32,642)
Foreign	104	130	142
Loss before taxes	$ (21,680)	$ (24,598)	$ (32,500)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Current	$ 102	$ 46	$ 8
Deferred	(107)	73	(5)
Taxes on income	(5)	119	3
Domestic
Foreign	(5)	119	3
Taxes on income	$ (5)	$ 119	$ 3

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Carry forward tax losses	$ 28,033	$ 24,969
Research and development carry forward expenses-temporary differences	1,567	1,282
Accrual and reserves	241	139
Deferred tax assets before valuation allowance	29,841	26,390
Valuation allowance	(29,655)	(26,311)	$ (22,560)	$ (16,196)
Net deferred tax assets	$ 186	$ 79

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ (26,311)	$ (22,560)	$ (16,196)
Changes due to amendments to tax laws and exchange rate differences	1,393	1,806	917,000
Adjustment previous year loss		(591)
Additions during the year	(4,737)	(4,966)	(7,281)
Balance at end of year	$ (29,655)	$ (26,311)	$ (22,560)

Income Taxes (Details 4)

Income Taxes (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Loss before taxes, as reported in the consolidated statements of operations	$ (21,680)	$ (24,598)	$ (32,500)
Statutory tax rate	23.00%	24.00%	25.00%
Theoretical tax benefits on the above amount at the Israeli statutory tax rate	$ (4,986)	$ (5,904)	$ (8,125)
Income tax at rate other than the Israeli statutory tax rate	5	17	10
Non-deductible expenses including equity based compensation expenses and other	631	878	857
Operating losses and other temporary differences for which valuation allowance was provided	4,737	4,966	7,281
Other	(392)	162	(20)
Actual tax expense	$ (5)	$ 119	$ 3

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	Dec. 29, 2010	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes (Textual)
Statutory tax rate		23.00%	24.00%	25.00%
Effect of tax rate change on deferred tax expense			$ 58
Beneficiary enterprise from productive activity, tax exemption period		10 years
Beneficiary enterprise from productive activity, maximum time from period of election for tax exemption		12 years
Carry-forward losses		$ 121,900
Description of income tax law for encouragement of capital investments	The Knesset approved an additional amendment to the Law for the Encouragement of Capital Investments, 1959. According to the amendment, a reduced uniform corporate tax rate for exporting industrial enterprises (over 25%) was established. The reduced tax rate will not be program dependent and will apply to the industrial enterprise’s entire income. The tax rates for industrial enterprises have been reduced. In August 2013, the Israeli Knesset approved an amendment to the Investment Law, pursuant to which the rates for development area A will be 9% and for the rest of the country- 16% in 2014 and thereafter. The Amendment also prescribes that any dividends distributed to individuals or foreign residents from a preferred enterprise’s earnings as above will be subject to taxes at a rate of 20% (subject to tax treaty benefits)			The Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law for the Encouragement of Capital Investments (“the Amendment”) was published. According to the Amendment, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2017 (and thereafter the tax rate applicable to preferred enterprises located in other areas remains at 16%).
Minimum [Member]
Income Taxes (Textual)
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income		10.00%
Maximum [Member]
Income Taxes (Textual)
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income		25.00%
RRI [Member]
Income Taxes (Textual)
Statutory tax rate		21.00%	21.00%	40.00%
Carry-forward losses		$ 140
Net operating carry-forward losses, terms		20 years
RRG [Member]
Income Taxes (Textual)
Statutory tax rate		30.00%	30.00%	30.00%
Israeli [Member]
Income Taxes (Textual)
Statutory tax rate		23.00%	24.00%	25.00%

Financial Expenses, Net (Detail

Financial Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ 42	$ (188)	$ 85
Financial expenses related to loan agreement with Kreos	2,398	2,451	1,976
Bank commissions	26	30	34
Income related to hedging transactions			(36)
Financial expenses, net	$ 2,466	$ 2,293	$ 2,059

Geographic Information and Ma_3

Geographic Information and Major Customer and Product Data (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017		Dec. 31, 2016
Revenue, Major Customer [Line Items]
Total revenues	$ 6,545	$ 7,753	[1]	$ 5,869	[1]
Israel [Member]
Revenue, Major Customer [Line Items]
Total revenues
United States [Member]
Revenue, Major Customer [Line Items]
Total revenues	3,558	4,598		3,741
Europe [Member]
Revenue, Major Customer [Line Items]
Total revenues	2,807	3,094		1,144
Asia-Pacific [Member]
Revenue, Major Customer [Line Items]
Total revenues	22	61		984
Latin America [Member]
Revenue, Major Customer [Line Items]
Total revenues	58
Africa [Member]
Revenue, Major Customer [Line Items]
Total revenues	$ 100
[1]	As noted above, prior period amounts have not been adjusted under the modified retrospective method.

Geographic Information and Ma_4

Geographic Information and Major Customer and Product Data (Details 1) - USD ($) $ in Thousands		Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets		$ 626	$ 840
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	206	298
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	330	342
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 90	$ 200
[1]	Long-lived assets are comprised of property and equipment, net.

Geographic Information and Ma_5

Geographic Information and Major Customer and Product Data (Details 2)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total revenues [Member] | Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration risk	38.00%	35.20%	33.30%

Geographic Information and Ma_6

Geographic Information and Major Customer and Product Data (Details Textual)	12 Months Ended
	Dec. 31, 2018segment
Geographic Information and Major Customer and Product Data (Textual)
Number of reportable segments	1